US20090062909A1 - Stent with polymer coating containing amorphous rapamycin - Google Patents

Stent with polymer coating containing amorphous rapamycin Download PDF

Info

Publication number
US20090062909A1
US20090062909A1 US11/995,685 US99568506A US2009062909A1 US 20090062909 A1 US20090062909 A1 US 20090062909A1 US 99568506 A US99568506 A US 99568506A US 2009062909 A1 US2009062909 A1 US 2009062909A1
Authority
US
United States
Prior art keywords
rapamycin
stent
coating
polymer coating
peva
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/995,685
Inventor
Doug Taylor
James DeYoung
Jim McCain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MiCell Technologies Inc
Original Assignee
MiCell Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MiCell Technologies Inc filed Critical MiCell Technologies Inc
Priority to US11/995,685 priority Critical patent/US20090062909A1/en
Assigned to MICELL TECHNOLOGIES, INC. reassignment MICELL TECHNOLOGIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TAYLOR, DOUG, DEYOUNG, JAMES, MCCLAIN, JIM
Publication of US20090062909A1 publication Critical patent/US20090062909A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02Inorganic materials
    • A61L31/022Metals or alloys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2002/821Ostial stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001Designing or manufacturing processes
    • A61F2240/002Designing or making customized prostheses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606Coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00Materials or methods for coatings medical devices
    • A61L2420/08Coatings comprising two or more layers

Definitions

  • DES drug eluting stents
  • Such localized delivery of these agents avoids the problems of systemic administration, which may be accompanied by unwanted effects on other parts of the body, or because administration to the afflicted body part requires a high concentration of pharmaceutical or biological agent that may not be achievable by systemic administration.
  • the coating may provide for controlled release, including long-term or sustained release, of a pharmaceutical or biological agent.
  • biomedical implants may be coated with materials to provide beneficial surface properties, such as enhanced biocompatibility or lubriciousness.
  • the present invention provides a coated coronary stent comprising: a stainless steel sent framework coated with a primer layer of Parylene C; and a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating.
  • PBMA polybutyl methacrylate
  • PEVA polyethylene-co-vinyl acetate
  • rapamycin rapamycin
  • the invention provides coated stents, wherein rapamycin is in the form of particles having an average diameter from 2 nm to 500 nm.
  • the invention provides coated stents, wherein the rapamycin-polymer coating has a thickness of about 1 to about 30 microns.
  • the coating is preferably substantially free of solvent residue.
  • the invention provides a coated stent, wherein the rapamycin-polymer coating is sintered in dense carbon dioxide at a temperature of about 40 C to about 60 C, whereby bulk properties and adhesion of the coating to the stent are improved without altering the quality of the rapamycin, PBMA or PEVA.
  • the rapamycin-polymer coating covers substantially the entire surface of the stent framework and/or the rapamycin-polymer coating is substantially free of aggregated particles.
  • the invention provides a stent coated with a polymer and rapamycin comprising: a stainless steel stent framework coated with a primer layer of Parylene C; and a rapamycin-polymer coating disposed on the stent framework, wherein the rapamycin-polymer coating comprises PBMA, PEVA; and rapamycin substantially uniformly dispersed within the rapamycin-polymer coating, wherein substantially all of rapamycin in the coating is in amorphous form, wherein disposing the coating is carried out by a spray coating process whereby rapamycin spray particles are formed by rapid expansion of a supercritical or near critical fluid mixture, and the rapamycin spray particles and the stent framework are oppositely charged so that the spray particles are electrostatically attracted to the stent framework.
  • the spray coating process is carried out under RESS condition.
  • the supercritical or near critical fluid mixture preferably comprises PBMA, PEVA and rapamycin dissolved in dimethylether, chlorofluorocarbon, hydrofluorocarbon, carbon dioxide or mixtures thereof.
  • FIG. 1 Rapid Expansion of Supercritical Solutions (RESS) process equipment see C. Domingo et al, Journal of Supercritical Fluids 10, 39-55 (1997)
  • FIG. 2 Infrared spectra of each component and the spray coating mixture. Individual peaks for each component are labeled.
  • FIG. 3 Stents coated (top panel) and sintered under different conditions (lower two panels) with rapamycin, PEVA and PBMA. All stent surfaces are coated
  • FIG. 4 Infrared spectra with all components coated, before and after sintering. The spectra indicate that no damage is done to the coating during the sintering process.
  • FIG. 5 XRD for RESS sprayed and as received rapamycin.
  • the RESS sprayed rapamycin does not show any diffraction peaks indicating the RESS sprayed material is in amorphous form
  • Compressed fluid refers to a fluid of appreciable density (e.g., >0.2 g/cc) that is a gas at standard temperature and pressure.
  • Supercritical fluid refers to a compressed fluid under conditions wherein the temperature is at least 80% of the critical temperature of the fluid and the pressure is at least 50% of the critical pressure of the fluid.
  • substances that demonstrate supercritical or near critical behavior suitable for the present invention include, but are not limited to carbon dioxide, isobutylene, ammonia, water, methanol, ethanol, ethane, propane, butane, pentane, dimethyl ether, xenon, sulfur hexafluoride, halogenated and partially halogenated materials such as chlorofluorocarbons, hydrochlorofluoro carbons, hydrofluorocarbons, perfluorocarbons (such as perfluoromethane and perfluoropropane, chloroform, trichloro-fluoromethane, dichloro-difluoromethane, dichloro-tetrafluoroethane) and mixtures thereof.
  • chlorofluorocarbons such as chlorofluorocarbons, hydrochlorofluoro carbons, hydrofluorocarbons, perfluorocarbons (such as perfluoromethane and perfluoropropane, chloroform, trich
  • “Sintering” as used herein refers to the process by which the polymer or polymers form continuous coating by treatment of the coated substrate with a densified gas, compressed fluid, compressed gas, near critical fluid or supercritical fluid that is a non-solvent for both the polymer and the pharmaceutical agent and biological agents, but an agent that induces formation of continuous domains of polymer.
  • a densified gas, compressed fluid, compressed gas, near critical fluid or supercritical fluid that is a non-solvent for both the polymer and the pharmaceutical agent and biological agents, but an agent that induces formation of continuous domains of polymer.
  • Rapid Expansion of Supercritical Solutions involves the dissolution of a polymer into a compressed fluid, typically a supercritical fluid, followed by rapid expansion into a chamber at lower pressure, typically near atmospheric conditions.
  • the atmosphere of the chamber is maintained in an electrically neutral state by maintaining an isolating “cloud” of gas in the chamber. Carbon dioxide or other appropriate gas is employed to prevent electrical charge is transferred from the substrate to the surrounding environment.
  • Electrostatic capture refers to the collection of the spray-produced particles upon a substrate that has a different electrostatic potential than the sprayed particles.
  • the substrate is at an attractive electronic potential with respect to the particles exiting, which results in the capture of the particles upon the substrate. i.e. the substrate and particles are oppositely charged, and the particles transport through the fluid medium of the capture vessel onto the surface of the substrate is enhanced via electrostatic attraction. This may be achieved by charging the particles and grounding the substrate or conversely charging the substrate and grounding the particles, or by some other process, which would be easily envisaged by one of skill in the art of electrostatic capture.
  • Open vessel refers to a vessel open to the outside atmosphere, and thus at substantially the same temperature and pressure as the outside atmosphere.
  • “Closed vessel” as used herein refers to a vessel sealed from the outside atmosphere, and thus may be at significantly different temperatures and pressures to the outside atmosphere. Rapamycin is an immunosuppressive lactam macrolide that is produced by Streptomyces hygroscopicus , and having the structure depicted in Formula:
  • the present invention provides a coated coronary stent comprising: a stainless steel sent framework coated with a primer layer of Parylene C; and a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating.
  • PBMA polybutyl methacrylate
  • PEVA polyethylene-co-vinyl acetate
  • the PBMA, PEVA and rapamycin are present in a ratio of about 1:1:1.
  • the invention provides coated stents, wherein rapamycin is in the form of particles having an average diameter from 2 nm to 500 nm.
  • the invention provides coated stents, wherein the rapamycin-polymer coating has a thickness of about 1 to about 30 microns.
  • the coating is preferably substantially free of solvent residue.
  • the invention provides a coated stent, wherein the rapamycin-polymer coating is sintered in dense carbon dioxide at a temperature of about 40 C to about 60 C, whereby bulk properties and adhesion of the coating to the stent are improved without altering the quality of the rapamycin, PBMA or PEVA.
  • the rapamycin-polymer coating covers substantially the entire surface of the stent framework.
  • the invention encompasses embodiments wherein the rapamycin-polymer coating is substantially free of aggregated particles.
  • the invention also provides a stent coated with a polymer and rapamycin comprising: a stainless steel stent framework coated with a primer layer of Parylene C; and a rapamycin-polymer polymer coating disposed on the stent framework, wherein the rapamycin-polymer coating comprises PBMA, PEVA; and rapamycin substantially uniformly dispersed within the rapamycin-polymer coating, wherein substantially all of rapamycin in the coating is in amorphous form, wherein disposing the coating is carried out by a spray coating process whereby rapamycin spray particles are formed by rapid expansion of a supercritical or near critical fluid mixture, and the rapamycin spray particles and the stent framework are oppositely charged so that the spray particles are electrostatically attracted to the stent framework.
  • the spray coating process is carried out under RESS condition.
  • the supercritical or near critical fluid mixture preferably comprises PBMA, PEVA and rapamycin dissolved in dimethylether, chlorofluorocarbon, hydrofluorocarbon, carbon dioxide or mixtures thereof.
  • FIG. 1 The RESS process equipment used in the present studies is depicted in FIG. 1 . This is a common design for a RESS apparatus see C. Domingo et al, Journal of Supercritical Fluids 10, 39-55 (1997).
  • a solution containing rapamycin that is saturated in a solvent or supersaturated in a solvent is sprayed at a flow rate sufficient to achieve flow into a chamber of known volume pressurized above ambient pressure and containing a coronary stent.
  • the system temperature is held constant or allowed to vary so that any number of points in the phase diagrams of the solution or mixture or any of its individual components can be mapped in pressure-temperature, volume-pressure or pressure-volume space constituting liquid, gas or supercritical CO 2 conditions.
  • CO 2 in any single phase or combination of phases flows through the chamber at a mass flow rate of 5 gm/min to some multiple of this flow rate.
  • the solute and solvent flow that is a solution of the therapeutic compound and suitable solvent for the chosen solute or solutes cease but CO 2 flow continues for an additional period of time maintaining constant pressure during this period. After this time period, the pressure is dropped to atmospheric pressure.
  • the particles are attracted to the stent by charging the substrate oppositely to that of the sprayed particle charge by applying a voltage that is greater than 5000 V but less than the ionization potential of the most easily ionized component of the mixture.
  • the particles may also traverse an electromagnetic field such that the field is used to guide the particle to a target.
  • the individual bands used for compositional analysis were determined by spray coating Si wafer chips with each component separately.
  • the coating thickness was determined gravimetrically and calculated from the density of the materials. It was assumed that the layer is fully dense. The thickness can be controlled by varying the spray time.
  • the coating In the as sprayed state, the coating lacks strong adhesion to the substrate. Sintering the coated substrate (see FIG. 3 ) dramatically improves coating adhesion while leaving the components unaltered as the infrared spectra shown in FIG. 4 confirm.
  • the coating is sintered in a supercritical carbon dioxide environment allowing mild sintering conditions to be used with temperature below 80 C.
  • FIG. 4 shows Infrared spectra with all components coated, before and after sintering.
  • the spectra indicate that no damage is done to the coating during the sintering process.
  • the spectra demonstrate that the sintering process does not adversely impact the coating since no new stretches appear in the after sintering spectrum.
  • FIG. 5 shows XRD data taken for an authentic rapamycin sample (as received rapamycin) and RESS sprayed rapamycin.
  • the RESS sprayed rapamycin does not show any diffraction peaks indicating the RESS sprayed material is in amorphous form. In other words, the RESS sprayed rapamycin lacks any crystallinity as indicated by the absence of diffraction peaks in the XRD.

Abstract

A coated coronary stent, comprising: a stainless steel sent framework coated with a primer layer of Parylene C; and a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating.

Description

    BACKGROUND OF THE INVENTION
  • It is often beneficial to provide coatings onto substrates, such that the surfaces of such substrates have desired properties or effects. It is useful to coat biomedical implants to provide for the localized delivery of pharmaceutical or biological agents to target specific locations within the body, for therapeutic or prophylactic benefit. One area of particular interest is drug eluting stents (DES) that has recently been reviewed by Ong and Sermuys in Nat. Clin. Pract. Cardiovasc. Med., (December 2005), Vol 2, No 12, 647. Typically such pharmaceutical or biological agents are co-deposited with a polymer. Such localized delivery of these agents avoids the problems of systemic administration, which may be accompanied by unwanted effects on other parts of the body, or because administration to the afflicted body part requires a high concentration of pharmaceutical or biological agent that may not be achievable by systemic administration. The coating may provide for controlled release, including long-term or sustained release, of a pharmaceutical or biological agent. Additionally, biomedical implants may be coated with materials to provide beneficial surface properties, such as enhanced biocompatibility or lubriciousness.
  • Conventional solvent-based spray coating processes are generally hampered by inefficiencies related to collection of the coating constituents onto the substrate and the consistency of the final coating. As the size of the substrate decreases, and as the mechanical complexity increases, it grows increasingly difficult to uniformly coat all surfaces of a substrate.
  • What is needed is a cost-effective method for depositing inert polymers and pharmaceutical or biological agents, such as rapamycin onto a substrate, where the collection process is efficient, the coating produced is conformal, substantially defect-free and uniform, and the composition of the coating can be regulated.
  • SUMMARY OF THE INVENTION
  • The present invention provides a coated coronary stent comprising: a stainless steel sent framework coated with a primer layer of Parylene C; and a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating. In one embodiment, the PBMA, PEVA and rapamycin are present in a ratio of about 1:1:1.
  • In one aspect, the invention provides coated stents, wherein rapamycin is in the form of particles having an average diameter from 2 nm to 500 nm.
  • In another aspect, the invention provides coated stents, wherein the rapamycin-polymer coating has a thickness of about 1 to about 30 microns. The coating is preferably substantially free of solvent residue.
  • In yet another aspect, the invention provides a coated stent, wherein the rapamycin-polymer coating is sintered in dense carbon dioxide at a temperature of about 40 C to about 60 C, whereby bulk properties and adhesion of the coating to the stent are improved without altering the quality of the rapamycin, PBMA or PEVA. Preferably, the rapamycin-polymer coating covers substantially the entire surface of the stent framework and/or the rapamycin-polymer coating is substantially free of aggregated particles.
  • In another aspect, the invention provides a stent coated with a polymer and rapamycin comprising: a stainless steel stent framework coated with a primer layer of Parylene C; and a rapamycin-polymer coating disposed on the stent framework, wherein the rapamycin-polymer coating comprises PBMA, PEVA; and rapamycin substantially uniformly dispersed within the rapamycin-polymer coating, wherein substantially all of rapamycin in the coating is in amorphous form, wherein disposing the coating is carried out by a spray coating process whereby rapamycin spray particles are formed by rapid expansion of a supercritical or near critical fluid mixture, and the rapamycin spray particles and the stent framework are oppositely charged so that the spray particles are electrostatically attracted to the stent framework. Preferably, the spray coating process is carried out under RESS condition. The supercritical or near critical fluid mixture preferably comprises PBMA, PEVA and rapamycin dissolved in dimethylether, chlorofluorocarbon, hydrofluorocarbon, carbon dioxide or mixtures thereof.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
  • FIG. 1. Rapid Expansion of Supercritical Solutions (RESS) process equipment see C. Domingo et al, Journal of Supercritical Fluids 10, 39-55 (1997)
  • FIG. 2. Infrared spectra of each component and the spray coating mixture. Individual peaks for each component are labeled.
  • FIG. 3. Stents coated (top panel) and sintered under different conditions (lower two panels) with rapamycin, PEVA and PBMA. All stent surfaces are coated
  • FIG. 4. Infrared spectra with all components coated, before and after sintering. The spectra indicate that no damage is done to the coating during the sintering process.
  • FIG. 5. XRD for RESS sprayed and as received rapamycin. The RESS sprayed rapamycin does not show any diffraction peaks indicating the RESS sprayed material is in amorphous form
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention is explained in greater detail below. This description is not intended to be a detailed catalog of all the different ways in which the invention may be implemented, or all the features that may be added to the instant invention. For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. In addition, numerous variations and additions to the various embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure, which do not depart from the instant invention. Hence, the following specification is intended to illustrate some particular embodiments of the invention, and not to exhaustively specify all permutations, combinations and variations thereof.
  • DEFINITIONS
  • As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.
  • “Compressed fluid” as used herein refers to a fluid of appreciable density (e.g., >0.2 g/cc) that is a gas at standard temperature and pressure. “Supercritical fluid”, “near-critical fluid”, “near-supercritical fluid”, “critical fluid”, “densified fluid” or “densified gas” as used herein refers to a compressed fluid under conditions wherein the temperature is at least 80% of the critical temperature of the fluid and the pressure is at least 50% of the critical pressure of the fluid. Examples of substances that demonstrate supercritical or near critical behavior suitable for the present invention include, but are not limited to carbon dioxide, isobutylene, ammonia, water, methanol, ethanol, ethane, propane, butane, pentane, dimethyl ether, xenon, sulfur hexafluoride, halogenated and partially halogenated materials such as chlorofluorocarbons, hydrochlorofluoro carbons, hydrofluorocarbons, perfluorocarbons (such as perfluoromethane and perfluoropropane, chloroform, trichloro-fluoromethane, dichloro-difluoromethane, dichloro-tetrafluoroethane) and mixtures thereof.
  • “Sintering” as used herein refers to the process by which the polymer or polymers form continuous coating by treatment of the coated substrate with a densified gas, compressed fluid, compressed gas, near critical fluid or supercritical fluid that is a non-solvent for both the polymer and the pharmaceutical agent and biological agents, but an agent that induces formation of continuous domains of polymer. Through the sintering process, the adhesion properties of the coating are improved to reduce flaking of detachment of the coating from the substrate during manipulation.
  • “Rapid Expansion of Supercritical Solutions” or “RESS” as used herein involves the dissolution of a polymer into a compressed fluid, typically a supercritical fluid, followed by rapid expansion into a chamber at lower pressure, typically near atmospheric conditions. The rapid expansion of the supercritical fluid solution through a small opening, with its accompanying decrease in density, reduces the dissolution capacity of the fluid and results in the nucleation and growth of polymer particles. The atmosphere of the chamber is maintained in an electrically neutral state by maintaining an isolating “cloud” of gas in the chamber. Carbon dioxide or other appropriate gas is employed to prevent electrical charge is transferred from the substrate to the surrounding environment.
  • “Electrostatically charged” or “electrical potential” or “electrostatic capture” as used herein refers to the collection of the spray-produced particles upon a substrate that has a different electrostatic potential than the sprayed particles. Thus, the substrate is at an attractive electronic potential with respect to the particles exiting, which results in the capture of the particles upon the substrate. i.e. the substrate and particles are oppositely charged, and the particles transport through the fluid medium of the capture vessel onto the surface of the substrate is enhanced via electrostatic attraction. This may be achieved by charging the particles and grounding the substrate or conversely charging the substrate and grounding the particles, or by some other process, which would be easily envisaged by one of skill in the art of electrostatic capture.
  • “Open vessel” as used herein refers to a vessel open to the outside atmosphere, and thus at substantially the same temperature and pressure as the outside atmosphere.
  • “Closed vessel” as used herein refers to a vessel sealed from the outside atmosphere, and thus may be at significantly different temperatures and pressures to the outside atmosphere. Rapamycin is an immunosuppressive lactam macrolide that is produced by Streptomyces hygroscopicus, and having the structure depicted in Formula:
  • Figure US20090062909A1-20090305-C00001
  • See, e.g., McAlpine, J. B., et al., J. Antibiotics (1991) 44: 688; Schreiber, S. L., et al., J. Am. Chem. Soc. (1991) 113: 7433; U.S. Pat. No. 3,929,992.
  • The present invention provides a coated coronary stent comprising: a stainless steel sent framework coated with a primer layer of Parylene C; and a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating.
  • In one embodiment, the PBMA, PEVA and rapamycin are present in a ratio of about 1:1:1.
  • In another embodiment, the invention provides coated stents, wherein rapamycin is in the form of particles having an average diameter from 2 nm to 500 nm.
  • In another embodiment, the invention provides coated stents, wherein the rapamycin-polymer coating has a thickness of about 1 to about 30 microns. The coating is preferably substantially free of solvent residue.
  • In yet another embodiment, the invention provides a coated stent, wherein the rapamycin-polymer coating is sintered in dense carbon dioxide at a temperature of about 40 C to about 60 C, whereby bulk properties and adhesion of the coating to the stent are improved without altering the quality of the rapamycin, PBMA or PEVA. Preferably, the rapamycin-polymer coating covers substantially the entire surface of the stent framework.
  • The invention encompasses embodiments wherein the rapamycin-polymer coating is substantially free of aggregated particles.
  • The invention also provides a stent coated with a polymer and rapamycin comprising: a stainless steel stent framework coated with a primer layer of Parylene C; and a rapamycin-polymer polymer coating disposed on the stent framework, wherein the rapamycin-polymer coating comprises PBMA, PEVA; and rapamycin substantially uniformly dispersed within the rapamycin-polymer coating, wherein substantially all of rapamycin in the coating is in amorphous form, wherein disposing the coating is carried out by a spray coating process whereby rapamycin spray particles are formed by rapid expansion of a supercritical or near critical fluid mixture, and the rapamycin spray particles and the stent framework are oppositely charged so that the spray particles are electrostatically attracted to the stent framework. Preferably, the spray coating process is carried out under RESS condition. The supercritical or near critical fluid mixture preferably comprises PBMA, PEVA and rapamycin dissolved in dimethylether, chlorofluorocarbon, hydrofluorocarbon, carbon dioxide or mixtures thereof.
  • EXAMPLES
  • The following examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.
  • Example 1
  • The RESS process equipment used in the present studies is depicted in FIG. 1. This is a common design for a RESS apparatus see C. Domingo et al, Journal of Supercritical Fluids 10, 39-55 (1997).
  • A solution containing rapamycin that is saturated in a solvent or supersaturated in a solvent is sprayed at a flow rate sufficient to achieve flow into a chamber of known volume pressurized above ambient pressure and containing a coronary stent. The system temperature is held constant or allowed to vary so that any number of points in the phase diagrams of the solution or mixture or any of its individual components can be mapped in pressure-temperature, volume-pressure or pressure-volume space constituting liquid, gas or supercritical CO2 conditions. CO2 in any single phase or combination of phases flows through the chamber at a mass flow rate of 5 gm/min to some multiple of this flow rate. After a period of time ranging from seconds to minutes or hours have elapsed, the solute and solvent flow that is a solution of the therapeutic compound and suitable solvent for the chosen solute or solutes cease but CO2 flow continues for an additional period of time maintaining constant pressure during this period. After this time period, the pressure is dropped to atmospheric pressure. During the spray coating process the particles are attracted to the stent by charging the substrate oppositely to that of the sprayed particle charge by applying a voltage that is greater than 5000 V but less than the ionization potential of the most easily ionized component of the mixture. The particles may also traverse an electromagnetic field such that the field is used to guide the particle to a target.
  • Example 2
  • The ability to uniformly coat arterial stents with rapamycin with controlled composition and thickness using electrostatic capture in a rapid expansion of supercritical solution (RESS) experimental series has been demonstrated. This technique involves spraying an equal part mixture of the therapeutic compound such as rapamycin and polymers such as PBMA and PEVA using a spray coating and collection technique described herein. To determine coating composition, infrared spectroscopy was used to collect the spectrum of a silicon wafer chip coated simultaneously with an arterial stent (FIG. 2). Unique absorption bands were identified for each mixture component and band area was used as a metric to determine incorporation of each compound in the coating.
  • The individual bands used for compositional analysis were determined by spray coating Si wafer chips with each component separately. The coating thickness was determined gravimetrically and calculated from the density of the materials. It was assumed that the layer is fully dense. The thickness can be controlled by varying the spray time.
  • In the as sprayed state, the coating lacks strong adhesion to the substrate. Sintering the coated substrate (see FIG. 3) dramatically improves coating adhesion while leaving the components unaltered as the infrared spectra shown in FIG. 4 confirm. The coating is sintered in a supercritical carbon dioxide environment allowing mild sintering conditions to be used with temperature below 80 C.
  • FIG. 4 shows Infrared spectra with all components coated, before and after sintering. The spectra indicate that no damage is done to the coating during the sintering process. The spectra demonstrate that the sintering process does not adversely impact the coating since no new stretches appear in the after sintering spectrum.
  • FIG. 5 shows XRD data taken for an authentic rapamycin sample (as received rapamycin) and RESS sprayed rapamycin. The RESS sprayed rapamycin does not show any diffraction peaks indicating the RESS sprayed material is in amorphous form. In other words, the RESS sprayed rapamycin lacks any crystallinity as indicated by the absence of diffraction peaks in the XRD.
  • While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims (13)

1. A coated coronary stent, comprising:
a stainless steel sent framework coated with a primer layer of Parylene C; and
a rapamycin-polymer coating having substantially uniform thickness disposed on the stent framework, wherein the rapamycin-polymer coating comprises polybutyl methacrylate (PBMA), polyethylene-co-vinyl acetate (PEVA) and rapamycin, wherein substantially all of the rapamycin in the coating is in amorphous form and substantially uniformly dispersed within the rapamycin-polymer coating.
2. The stent of claim 1, wherein PBMA, PEVA and rapamycin are present in a ratio of about 1:1:1.
3. The stent of claim 1, wherein rapamycin is in the form of particles having an average diameter from 2 nm to 500 nm.
4. The stent of claim 1, wherein said coating has a thickness of about 1 to about 30 microns.
5. The stent of claim 1, wherein said coating is substantially free of solvent residue.
6. The stent of claim 1, wherein the rapamycin-polymer coating is sintered in dense carbon dioxide at a temperature of about 50 C to about 60 C and a pressure below 1000 psig, whereby bulk properties and adhesion of the coating to said stent are improved without altering the quality of the rapamycin, PBMA or PEVA.
7. The stent of claim 1, wherein said rapamycin-polymer coating covers substantially the entire surface of said stent framework.
8. The stent of claim 1, wherein said rapamycin-polymer coating is substantially free of aggregated particles.
9. A stent coated with a polymer and rapamycin, comprising:
a stainless steel stent framework coated with a primer layer of Parylene C; and
a rapamycin-polymer coating disposed on the stent framework, wherein the rapamycin-polymer coating comprises PBMA, PEVA; and rapamycin substantially uniformly dispersed within the rapamycin-polymer coating, wherein substantially all of rapamycin in the coating is in amorphous form, wherein disposing said coating is carried out by a spray coating process whereby rapamycin spray particles are formed by rapid expansion of a supercritical or near critical fluid mixture, and said rapamycin spray particles and said stent framework are oppositely charged so that said spray particles are electrostatically attracted to said stent framework.
10. The stent of claim 9, wherein said spray coating process is carried out under RESS conditions.
11. The stent of claim 10, wherein said supercritical or near critical fluid mixture comprises PBMA, PEVA and rapamycin dissolved in dimethylether, chlorofluorocarbon, hydrofluorocarbon, carbon dioxide or mixtures thereof.
12. The stent of claim 10, wherein PBMA, PEVA and rapamycin are co-deposited from a single mixture.
13. The stent of claim 10, wherein PBMA, PEVA and rapamycin are separately deposited on the stent.
US11/995,685 2005-07-15 2006-07-14 Stent with polymer coating containing amorphous rapamycin Abandoned US20090062909A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/995,685 US20090062909A1 (en) 2005-07-15 2006-07-14 Stent with polymer coating containing amorphous rapamycin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69965005P 2005-07-15 2005-07-15
US76533906P 2006-02-03 2006-02-03
US11/995,685 US20090062909A1 (en) 2005-07-15 2006-07-14 Stent with polymer coating containing amorphous rapamycin
PCT/US2006/027322 WO2007011708A2 (en) 2005-07-15 2006-07-14 Stent with polymer coating containing amorphous rapamycin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/027322 A-371-Of-International WO2007011708A2 (en) 2005-07-15 2006-07-14 Stent with polymer coating containing amorphous rapamycin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/718,342 Continuation US10835396B2 (en) 2005-07-15 2015-05-21 Stent with polymer coating containing amorphous rapamycin

Publications (1)

Publication Number Publication Date
US20090062909A1 true US20090062909A1 (en) 2009-03-05

Family

ID=37669386

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/995,685 Abandoned US20090062909A1 (en) 2005-07-15 2006-07-14 Stent with polymer coating containing amorphous rapamycin
US14/718,342 Active US10835396B2 (en) 2005-07-15 2015-05-21 Stent with polymer coating containing amorphous rapamycin

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/718,342 Active US10835396B2 (en) 2005-07-15 2015-05-21 Stent with polymer coating containing amorphous rapamycin

Country Status (2)

Country Link
US (2) US20090062909A1 (en)
WO (1) WO2007011708A2 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095919A1 (en) * 2006-10-23 2008-04-24 Mcclain James B Holder For Electrically Charging A Substrate During Coating
US20090123515A1 (en) * 2005-07-15 2009-05-14 Doug Taylor Polymer coatings containing drug powder of controlled morphology
US20090186069A1 (en) * 2006-04-26 2009-07-23 Micell Technologies, Inc. Coatings Containing Multiple Drugs
US20090292351A1 (en) * 2008-04-17 2009-11-26 Micell Technologies, Inc. Stents having bioabsorbable layers
US20100015200A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug Delivery Medical Device
US20100030261A1 (en) * 2006-10-02 2010-02-04 Micell Technologies, Inc. Surgical Sutures Having Increased Strength
US20100063580A1 (en) * 2007-01-08 2010-03-11 Mcclain James B Stents having biodegradable layers
US20100211164A1 (en) * 2007-04-17 2010-08-19 Mcclain James B Stents having biodegradable layers
US20100228348A1 (en) * 2007-05-25 2010-09-09 Micell Technologies, Inc. Polymer Films for Medical Device Coating
US20100241220A1 (en) * 2009-03-23 2010-09-23 Mcclain James B Peripheral Stents Having Layers
US20100239635A1 (en) * 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
US20100256746A1 (en) * 2009-03-23 2010-10-07 Micell Technologies, Inc. Biodegradable polymers
US20100256748A1 (en) * 2009-04-01 2010-10-07 Micell Technologies, Inc. Coated stents
US20100272778A1 (en) * 2007-04-17 2010-10-28 Micell Technologies, Inc. Stents having controlled elution
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
US20110159069A1 (en) * 2008-12-26 2011-06-30 Shaw Wendy J Medical Implants and Methods of Making Medical Implants
US20110190864A1 (en) * 2010-02-02 2011-08-04 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US20110238161A1 (en) * 2010-03-26 2011-09-29 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
WO2011130448A1 (en) * 2010-04-16 2011-10-20 Micell Technologies, Inc. Stents having controlled elution
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US9636309B2 (en) 2010-09-09 2017-05-02 Micell Technologies, Inc. Macrolide dosage forms
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10835396B2 (en) 2005-07-15 2020-11-17 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US11904118B2 (en) 2010-07-16 2024-02-20 Micell Medtech Inc. Drug delivery medical device

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1400977B1 (en) 2010-07-01 2013-07-05 Euticals Spa NEW COMPLEXES OF PHARMACEUTICAL, SOLID, SOLUBLE IN WATER AND THEIR WATER SOLUTIONS FOR ORAL, OPHTHALMIC, TOPICAL OR PARENTERAL USE, CONTAINING A MACROLIDE AND SOME CYCLODEXTRINES.
US11406742B2 (en) 2014-07-18 2022-08-09 M.A. Med Alliance SA Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
CN104525944A (en) * 2014-12-23 2015-04-22 北京理工大学 High-energy beam-ultrasonic composite additive manufacturing method for metal materials
KR102601927B1 (en) * 2017-01-05 2023-11-15 삼성전자주식회사 Cover and electronic device including the same
CN111450064A (en) * 2020-04-09 2020-07-28 广州中医药大学(广州中医药研究院) Method for preparing sirolimus coated particles based on supercritical anti-solvent method, prepared sirolimus coated particles and application

Citations (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3087860A (en) * 1958-12-19 1963-04-30 Abbott Lab Method of prolonging release of drug from a precompressed solid carrier
US3087660A (en) * 1962-07-24 1963-04-30 Yankee Plasties Inc Two-step garment hanger
US4326532A (en) * 1980-10-06 1982-04-27 Minnesota Mining And Manufacturing Company Antithrombogenic articles
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US5158986A (en) * 1991-04-05 1992-10-27 Massachusetts Institute Of Technology Microcellular thermoplastic foamed with supercritical fluid
US5243023A (en) * 1991-08-28 1993-09-07 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polyimides containing amide and perfluoroisopropylidene connecting groups
US5340614A (en) * 1993-02-11 1994-08-23 Minnesota Mining And Manufacturing Company Methods of polymer impregnation
US5342621A (en) * 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US5356433A (en) * 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
US5569463A (en) * 1990-05-17 1996-10-29 Harbor Medical Devices, Inc. Medical device polymer
US5811032A (en) * 1995-09-19 1998-09-22 Mitsubishi Gas Chemical Company, Inc. Biodegradable water-soluble polymer
US5824049A (en) * 1995-06-07 1998-10-20 Med Institute, Inc. Coated implantable medical device
US5948020A (en) * 1995-05-01 1999-09-07 Sam Yang Co., Ltd. Implantable bioresorbable membrane and method for the preparation thereof
US5957975A (en) * 1997-12-15 1999-09-28 The Cleveland Clinic Foundation Stent having a programmed pattern of in vivo degradation
US6190699B1 (en) * 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6364903B2 (en) * 1999-03-19 2002-04-02 Meadox Medicals, Inc. Polymer coated stent
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6372246B1 (en) * 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
US6409716B1 (en) * 1989-12-15 2002-06-25 Scimed Life Systems, Inc. Drug delivery
US6414050B1 (en) * 1997-05-10 2002-07-02 University Of Nottingham Biofunctional polymers prepared in supercritical fluid
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6448315B1 (en) * 1999-02-17 2002-09-10 Bone Support Ab Method for the preparation of UHMWPE doped with an antioxidant and an implant made thereof
US20020133072A1 (en) * 1999-09-10 2002-09-19 Guo-Bin Wang Graft polymerization of substrate surfaces
US6461644B1 (en) * 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US6506213B1 (en) * 2000-09-08 2003-01-14 Ferro Corporation Manufacturing orthopedic parts using supercritical fluid processing techniques
US6517860B1 (en) * 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
US20030031699A1 (en) * 2002-09-30 2003-02-13 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
US6521258B1 (en) * 2000-09-08 2003-02-18 Ferro Corporation Polymer matrices prepared by supercritical fluid processing techniques
US6524698B1 (en) * 1990-09-27 2003-02-25 Helmuth Schmoock Fluid impermeable foil
US20030088307A1 (en) * 2001-11-05 2003-05-08 Shulze John E. Potent coatings for stents
US20030125800A1 (en) * 2001-11-05 2003-07-03 Shulze John E. Drug-delivery endovascular stent and method for treating restenosis
US20030143315A1 (en) * 2001-05-16 2003-07-31 Pui David Y H Coating medical devices
US20030180376A1 (en) * 2001-03-02 2003-09-25 Dalal Paresh S. Porous beta-tricalcium phosphate granules and methods for producing same
US6627246B2 (en) * 2000-05-16 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Process for coating stents and other medical devices using super-critical carbon dioxide
US20030185964A1 (en) * 2002-03-28 2003-10-02 Jan Weber Method for spray-coating a medical device having a tubular wall such as a stent
US20030204238A1 (en) * 2002-04-26 2003-10-30 Eugene Tedeschi Coated stent with crimpable coating
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6710059B1 (en) * 1999-07-06 2004-03-23 Endorecherche, Inc. Methods of treating and/or suppressing weight gain
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
US6736996B1 (en) * 1997-10-10 2004-05-18 North Carolina State University Compositions for protecting civil infrastructure
US20040106982A1 (en) * 1999-03-16 2004-06-03 Jalisi Marc M. Multilayer stent
US6749902B2 (en) * 2002-05-28 2004-06-15 Battelle Memorial Institute Methods for producing films using supercritical fluid
US6755871B2 (en) * 1999-10-15 2004-06-29 R.R. Street & Co. Inc. Cleaning system utilizing an organic cleaning solvent and a pressurized fluid solvent
US6756084B2 (en) * 2002-05-28 2004-06-29 Battelle Memorial Institute Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions
US20040126542A1 (en) * 2002-07-29 2004-07-01 Nitto Denko Corporation Pressure-sensitive adhesive tape or sheet
US6767558B2 (en) * 2000-03-10 2004-07-27 Pfizer Inc. Inhibiting oxidative degradation of pharmaceutical formulations
US6780475B2 (en) * 2002-05-28 2004-08-24 Battelle Memorial Institute Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions
US20040193177A1 (en) * 2003-03-31 2004-09-30 Houghton Michael J. Modified delivery device for coated medical devices
US20040193262A1 (en) * 2003-03-29 2004-09-30 Shadduck John H. Implants for treating ocular hypertension, methods of use and methods of fabrication
US6838528B2 (en) * 2001-01-19 2005-01-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
US6837611B2 (en) * 2001-12-28 2005-01-04 Metal Industries Research & Development Centre Fluid driven agitator used in densified gas cleaning system
US6838089B1 (en) * 1998-04-14 2005-01-04 Astrazeneca Ab Antigen delivery system and method of production
US20050003074A1 (en) * 1996-11-13 2005-01-06 Phoqus Pharmaceuticals Limited Method and apparatus for the coating of substrates for pharmaceutical use
US20050004661A1 (en) * 2001-01-11 2005-01-06 Lewis Andrew L Stens with drug-containing amphiphilic polymer coating
US20050010275A1 (en) * 2002-10-11 2005-01-13 Sahatjian Ronald A. Implantable medical devices
US20050015046A1 (en) * 2003-07-18 2005-01-20 Scimed Life Systems, Inc. Medical devices and processes for preparing same
US20050019747A1 (en) * 2002-08-07 2005-01-27 Anderson Daniel G. Nanoliter-scale synthesis of arrayed biomaterials and screening thereof
US20050049694A1 (en) * 2003-08-07 2005-03-03 Medtronic Ave. Extrusion process for coating stents
US6868123B2 (en) * 2001-12-07 2005-03-15 Motorola, Inc. Programmable motion estimation module with vector array unit
US20050069630A1 (en) * 2003-09-30 2005-03-31 Advanced Cardiovascular Systems, Inc. Stent mandrel fixture and method for selectively coating surfaces of a stent
US20050079274A1 (en) * 2003-10-14 2005-04-14 Maria Palasis Method for coating multiple stents
US6884823B1 (en) * 1997-01-16 2005-04-26 Trexel, Inc. Injection molding of polymeric material
US6884377B1 (en) * 1996-08-27 2005-04-26 Trexel, Inc. Method and apparatus for microcellular polymer extrusion
US6897205B2 (en) * 2001-01-31 2005-05-24 Roehm Gmbh & Co. Kg Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
US6905555B2 (en) * 2001-02-15 2005-06-14 Micell Technologies, Inc. Methods for transferring supercritical fluids in microelectronic and other industrial processes
US20050147734A1 (en) * 2004-01-07 2005-07-07 Jan Seppala Method and system for coating tubular medical devices
US20050175772A1 (en) * 2004-02-10 2005-08-11 Robert Worsham Apparatus and method for electrostatic spray coating of medical devices
US20050177223A1 (en) * 2003-09-18 2005-08-11 Palmaz Julio C. Medical devices having MEMs functionality and methods of making same
US20050191491A1 (en) * 2003-04-08 2005-09-01 Yulu Wang Polymer coating/encapsulation of nanoparticles using a supercritical antisolvent process
US6939569B1 (en) * 1998-06-19 2005-09-06 Oxibio, Inc. Medical device having anti-infective and contraceptive properties
US20050196424A1 (en) * 2003-05-02 2005-09-08 Chappa Ralph A. Medical devices and methods for producing the same
US20050216075A1 (en) * 2003-04-08 2005-09-29 Xingwu Wang Materials and devices of enhanced electromagnetic transparency
US20050238829A1 (en) * 2004-04-22 2005-10-27 John Motherwell Differentially coated medical devices, system for differentially coating medical devices, and coating method
US20060020325A1 (en) * 2004-07-26 2006-01-26 Robert Burgermeister Material for high strength, controlled recoil stent
US20060094744A1 (en) * 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
US20060121089A1 (en) * 2002-03-20 2006-06-08 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US20060136041A1 (en) * 2004-12-17 2006-06-22 Schmid Eric V Slide-and-lock stent
US20060134211A1 (en) * 2004-12-16 2006-06-22 Miv Therapeutics Inc. Multi-layer drug delivery device and method of manufacturing same
US20060193886A1 (en) * 2002-11-13 2006-08-31 Owens Gary K Medical devices with nanoporous layers and topcoats
US20060198868A1 (en) * 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
US20060222756A1 (en) * 2000-09-29 2006-10-05 Cordis Corporation Medical devices, drug coatings and methods of maintaining the drug coatings thereon
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
US7163715B1 (en) * 2001-06-12 2007-01-16 Advanced Cardiovascular Systems, Inc. Spray processing of porous medical devices
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US20070123977A1 (en) * 2000-03-15 2007-05-31 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20070196423A1 (en) * 2005-11-21 2007-08-23 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
US20070203569A1 (en) * 2006-02-24 2007-08-30 Robert Burgermeister Implantable device formed from polymer blends having modified molecular structures
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20080075753A1 (en) * 2006-09-25 2008-03-27 Chappa Ralph A Multi-layered coatings and methods for controlling elution of active agents
US7378105B2 (en) * 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US20080206304A1 (en) * 2007-02-27 2008-08-28 Boston Scientific Scimed, Inc. Medical devices having polymeric regions based on styrene-isobutylene copolymers
US20080213464A1 (en) * 2007-01-03 2008-09-04 Boston Scientific Scimed, Inc. Methods of applying coating to the inside surface of a stent
US20080255510A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20090105809A1 (en) * 2007-10-19 2009-04-23 Lee Michael J Implantable and lumen-supporting stents and related methods of manufacture and use

Family Cites Families (507)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3123077A (en) 1964-03-03 Surgical suture
US3457280A (en) 1967-06-12 1969-07-22 American Cyanamid Co Alpha-glycolide and methods for the isolation thereof
US3597449A (en) 1967-11-16 1971-08-03 American Cyanamid Co Stable glycolide and lactide composition
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (en) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Process for the production of micro-granules
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4000137A (en) 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
JPS5668674A (en) 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4474572A (en) 1981-09-29 1984-10-02 Syntex (U.S.A.) Inc. Implanting device and implant magazine
SE445884B (en) 1982-04-30 1986-07-28 Medinvent Sa DEVICE FOR IMPLANTATION OF A RODFORM PROTECTION
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
SE435444B (en) 1983-02-25 1984-10-01 Hakan Johansson Fishing gear with a fishing line made by a light guide
US4606347A (en) 1983-03-25 1986-08-19 Thomas J. Fogarty Inverted balloon catheter having sealed through lumen
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4734227A (en) 1983-09-01 1988-03-29 Battelle Memorial Institute Method of making supercritical fluid molecular spray films, powder and fibers
US4582731A (en) 1983-09-01 1986-04-15 Battelle Memorial Institute Supercritical fluid molecular spray film deposition and powder formation
US4734451A (en) 1983-09-01 1988-03-29 Battelle Memorial Institute Supercritical fluid molecular spray thin films and fine powders
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4985625A (en) 1986-03-06 1991-01-15 Finnigan Corporation Transfer line for mass spectrometer apparatus
US4762593A (en) 1986-06-13 1988-08-09 Youngner Philip G Distilling apparatus
US4758435A (en) 1986-08-11 1988-07-19 American Cyanamid Company Estradiol implant composition and method for preparation
JPH068902Y2 (en) 1988-04-19 1994-03-09 マツダ株式会社 Starting safety device for vehicle
US5106650A (en) 1988-07-14 1992-04-21 Union Carbide Chemicals & Plastics Technology Corporation Electrostatic liquid spray application of coating with supercritical fluids as diluents and spraying from an orifice
US4950239A (en) 1988-08-09 1990-08-21 Worldwide Medical Plastics Inc. Angioplasty balloons and balloon catheters
AU4191989A (en) 1988-08-24 1990-03-23 Marvin J. Slepian Biodegradable polymeric endoluminal sealing
US4931037A (en) 1988-10-13 1990-06-05 International Medical, Inc. In-dwelling ureteral stent and injection stent assembly, and method of using same
US4958625A (en) 1989-07-18 1990-09-25 Boston Scientific Corporation Biopsy needle instrument
DK0420488T3 (en) 1989-09-25 1993-08-30 Schneider Usa Inc Multilayer extrusion as a method for preparing angioplasty balloons
CA2026604A1 (en) 1989-10-02 1991-04-03 Rodney G. Wolff Articulated stent
US5000519A (en) 1989-11-24 1991-03-19 John Moore Towed vehicle emergency brake control system
JP2641781B2 (en) 1990-02-23 1997-08-20 シャープ株式会社 Method of forming semiconductor element isolation region
US5545208A (en) 1990-02-28 1996-08-13 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5360403A (en) 1990-05-16 1994-11-01 Lake Region Manufacturing Co., Inc. Balloon catheter with lumen occluder
US5320634A (en) 1990-07-03 1994-06-14 Interventional Technologies, Inc. Balloon catheter with seated cutting edges
US5090419A (en) 1990-08-23 1992-02-25 Aubrey Palestrant Apparatus for acquiring soft tissue biopsy specimens
US6248129B1 (en) 1990-09-14 2001-06-19 Quanam Medical Corporation Expandable polymeric stent with memory and delivery apparatus and method
CA2060635A1 (en) 1991-02-12 1992-08-13 Keith D'alessio Bioabsorbable medical implants
GB2253164B (en) 1991-02-22 1994-10-05 Hoechst Uk Ltd Improvements in or relating to electrostatic coating of substrates of medicinal products
US5195969A (en) 1991-04-26 1993-03-23 Boston Scientific Corporation Co-extruded medical balloons and catheter using such balloons
US5372676A (en) 1991-05-15 1994-12-13 Lowe; Michael Method for producing replicated paving stone
US5185776A (en) 1991-08-05 1993-02-09 Townsend Boyd E Cover for an x-ray cassette
US5366504A (en) 1992-05-20 1994-11-22 Boston Scientific Corporation Tubular medical prosthesis
US5125570A (en) 1991-12-30 1992-06-30 Robert Jones Delivery box signal device
US5697882A (en) 1992-01-07 1997-12-16 Arthrocare Corporation System and method for electrosurgical cutting and ablation
US5876452A (en) 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
DE69332950T2 (en) 1992-03-31 2004-05-13 Boston Scientific Corp., Natick BLOOD VESSEL FILTER
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5500180A (en) 1992-09-30 1996-03-19 C. R. Bard, Inc. Method of making a distensible dilatation balloon using a block copolymer
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5387313A (en) 1992-11-09 1995-02-07 Bmc Industries, Inc. Etchant control system
US5385776A (en) 1992-11-16 1995-01-31 Alliedsignal Inc. Nanocomposites of gamma phase polymers containing inorganic particulate material
EP0604022A1 (en) 1992-12-22 1994-06-29 Advanced Cardiovascular Systems, Inc. Multilayered biodegradable stent and method for its manufacture
US5324049A (en) 1992-12-23 1994-06-28 Xerox Corporation Mandrel with flared, dish shaped disk and process for using mandrel
ES2166370T3 (en) 1993-01-19 2002-04-16 Schneider Usa Inc IMPLANTABLE FILAMENT IN COMPOSITE MATERIAL.
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
ES2113094T3 (en) 1993-03-09 1998-04-16 Epic Therapeutics Inc THE MACROMOLECULAR MICROPARTICLES AND METHODS OF OBTAINING.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
EP0689465A1 (en) 1993-03-18 1996-01-03 Cedars-Sinai Medical Center Drug incorporating and releasing polymeric coating for bioprosthesis
US20020055710A1 (en) 1998-04-30 2002-05-09 Ronald J. Tuch Medical device for delivering a therapeutic agent and method of preparation
US5403347A (en) 1993-05-27 1995-04-04 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5350627A (en) 1993-06-11 1994-09-27 Camelot Technologies, Inc. Coated webs
US5380299A (en) 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
DE4336209C2 (en) 1993-09-10 1995-09-21 Michael Dr Simon Method for producing a vascular prosthesis coated with antithrombotic agents
US5632772A (en) 1993-10-21 1997-05-27 Corvita Corporation Expandable supportive branched endoluminal grafts
US5350361A (en) 1993-11-10 1994-09-27 Medtronic, Inc. Tri-fold balloon for dilatation catheter and related method
US5494620A (en) 1993-11-24 1996-02-27 United States Surgical Corporation Method of manufacturing a monofilament suture
US5626611A (en) 1994-02-10 1997-05-06 United States Surgical Corporation Composite bioabsorbable materials and surgical articles made therefrom
US6146356A (en) 1994-03-02 2000-11-14 Scimed Life Systems, Inc. Block copolymer elastomer catheter balloons
US5556383A (en) 1994-03-02 1996-09-17 Scimed Lifesystems, Inc. Block copolymer elastomer catheter balloons
US5733303A (en) 1994-03-17 1998-03-31 Medinol Ltd. Flexible expandable stent
US5843120A (en) 1994-03-17 1998-12-01 Medinol Ltd. Flexible-expandable stent
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
AU698393B2 (en) 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
AU703933B2 (en) 1994-07-12 1999-04-01 Berwind Pharmaceutical Services, Inc. Moisture barrier film coating composition, method, and coated form
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
NL9401690A (en) 1994-10-13 1996-05-01 Industrial Res Bv Body-implantable stent.
WO1996016691A1 (en) 1994-12-02 1996-06-06 Science Incorporated Medicament dispenser
AU4755696A (en) 1995-01-05 1996-07-24 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Surface-modified nanoparticles and method of making and using same
US5599576A (en) 1995-02-06 1997-02-04 Surface Solutions Laboratories, Inc. Medical apparatus with scratch-resistant coating and method of making same
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5605696A (en) 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US6120536A (en) 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
AU4952096A (en) 1995-04-19 1996-11-07 Schneider (Usa) Inc. Drug release coated stent
US5570537A (en) 1995-04-27 1996-11-05 Black; Douglas A. Electronic insecticidal cable
US6602281B1 (en) 1995-06-05 2003-08-05 Avantec Vascular Corporation Radially expansible vessel scaffold having beams and expansion joints
US5714007A (en) 1995-06-06 1998-02-03 David Sarnoff Research Center, Inc. Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate
US5674242A (en) 1995-06-06 1997-10-07 Quanam Medical Corporation Endoprosthetic device with therapeutic compound
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US5609629A (en) 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
CA2219659C (en) 1995-06-09 2008-03-18 Novartis Ag Rapamycin derivatives
US6256529B1 (en) 1995-07-26 2001-07-03 Burdette Medical Systems, Inc. Virtual reality 3D visualization for surgical procedures
JP3476604B2 (en) 1995-08-22 2003-12-10 鐘淵化学工業株式会社 Method for manufacturing stent with drug attached / coated
US5607442A (en) 1995-11-13 1997-03-04 Isostent, Inc. Stent with improved radiopacity and appearance characteristics
CA2192520A1 (en) 1996-03-05 1997-09-05 Ian M. Penn Expandable stent and method for delivery of same
NZ331269A (en) 1996-04-10 2000-01-28 Advanced Cardiovascular System Expandable stent, its structural strength varying along its length
US5669932A (en) 1996-05-29 1997-09-23 Isostent, Inc. Means for accurately positioning an expandable stent
CN1171966C (en) 1996-05-31 2004-10-20 东陶机器株式会社 Antifouling member and coating composition
US6143037A (en) 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US5876426A (en) 1996-06-13 1999-03-02 Scimed Life Systems, Inc. System and method of providing a blood-free interface for intravascular light delivery
FR2750897B1 (en) 1996-07-10 1998-09-18 Sames Sa TRIBOELECTRIC PROJECTOR, COATING PRODUCT PROJECTION INSTALLATION AND METHOD FOR CONTROLLING SUCH A PROJECTOR
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
JPH1029524A (en) 1996-07-15 1998-02-03 Toyota Motor Corp Wheel slip controller
US5871436A (en) 1996-07-19 1999-02-16 Advanced Cardiovascular Systems, Inc. Radiation therapy method and device
DE69722720T2 (en) 1996-07-24 2004-05-13 Cordis Corp., Miami Lakes Balloon catheter and method of use
US6013855A (en) 1996-08-06 2000-01-11 United States Surgical Grafting of biocompatible hydrophilic polymers onto inorganic and metal surfaces
DE19633901A1 (en) 1996-08-22 1998-02-26 Thomas Prof Dr Med Ischinger Vascular support in the form of a tube section-like support structure
US5807404A (en) 1996-09-19 1998-09-15 Medinol Ltd. Stent with variable features to optimize support and method of making such stent
US6193963B1 (en) 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
US6387121B1 (en) 1996-10-21 2002-05-14 Inflow Dynamics Inc. Vascular and endoluminal stents with improved coatings
US6530951B1 (en) 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
US6251980B1 (en) 1996-12-06 2001-06-26 Amcol International Corporation Nanocomposites formed by onium ion-intercalated clay and rigid anhydride-cured epoxy resins
US5871437A (en) 1996-12-10 1999-02-16 Inflow Dynamics, Inc. Radioactive stent for treating blood vessels to prevent restenosis
FR2758253B1 (en) 1997-01-10 1999-04-02 Nycomed Lab Sa IMPLANTABLE DEVICE FOR THE TREATMENT OF A BODY DUCT
DE29702671U1 (en) 1997-02-17 1997-04-10 Jomed Implantate Gmbh Stent
BR9808109A (en) 1997-03-31 2000-03-08 Neorx Corp Therapeutic smooth muscle vascular cell inhibitor
US8172897B2 (en) 1997-04-15 2012-05-08 Advanced Cardiovascular Systems, Inc. Polymer and metal composite implantable medical devices
IT1292295B1 (en) 1997-04-29 1999-01-29 Sorin Biomedica Cardio Spa ANGIOPLASTIC STENT
FR2762777B1 (en) 1997-05-05 1999-10-22 Patrick Sabaria VASCULAR AND CORONARY EXTENDERS, USUALLY DESIGNATED UNDER THE NAME OF "STENT"
DE19720115C2 (en) 1997-05-14 1999-05-20 Jomed Implantate Gmbh Stent graft
WO1998051238A1 (en) 1997-05-14 1998-11-19 Novo Rps Ulc Expandable stent and method for production of same
DE29708689U1 (en) 1997-05-15 1997-07-17 Jomed Implantate Gmbh Coronary stent
US5913895A (en) 1997-06-02 1999-06-22 Isostent, Inc. Intravascular stent with enhanced rigidity strut members
US6416779B1 (en) 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6433154B1 (en) 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US6245103B1 (en) 1997-08-01 2001-06-12 Schneider (Usa) Inc Bioabsorbable self-expanding stent
US6077880A (en) 1997-08-08 2000-06-20 Cordis Corporation Highly radiopaque polyolefins and method for making the same
CA2298543A1 (en) 1997-08-13 1999-02-25 James Barry Loading and release of water-insoluble drugs
ATE307584T1 (en) 1997-08-28 2005-11-15 Nissan Chemical Ind Ltd AGENT FOR PROMOTING AND ENHANCEMENT NEOVASCULARIZATION
DE29716476U1 (en) 1997-09-13 1997-12-18 Convent Gerd Stenosis treatment stent
DE29716467U1 (en) 1997-09-15 1998-02-26 Loh Kg Rittal Werk Housing structure for electrical or electronic installations
US8257725B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
US6042606A (en) 1997-09-29 2000-03-28 Cook Incorporated Radially expandable non-axially contracting surgical stent
US6071308A (en) 1997-10-01 2000-06-06 Boston Scientific Corporation Flexible metal wire stent
ATE382309T1 (en) 1997-11-07 2008-01-15 Salviac Ltd EMBOLIC PROTECTION DEVICE
DE19881727D2 (en) 1997-11-24 2001-01-04 Herbert P Jennissen Process for immobilizing mediator molecules on inorganic and metallic implant materials
WO1999034750A1 (en) 1998-01-06 1999-07-15 Bioamide, Inc. Bioabsorbable fibers and reinforced composites produced therefrom
US6129755A (en) 1998-01-09 2000-10-10 Nitinol Development Corporation Intravascular stent having an improved strut configuration
WO1999044543A1 (en) 1998-03-04 1999-09-10 Scimed Life Systems, Inc. Improved stent cell configurations
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US8029561B1 (en) 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
DE19822157B4 (en) 1998-05-16 2013-01-10 Abbott Laboratories Vascular Enterprises Ltd. Radially expandable stent for implantation in a body vessel
FR2780057B1 (en) 1998-06-18 2002-09-13 Sanofi Sa PHENOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US7004962B2 (en) 1998-07-27 2006-02-28 Schneider (Usa), Inc. Neuroaneurysm occlusion and delivery device and method of using same
US8070796B2 (en) 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US7967855B2 (en) 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US6461380B1 (en) 1998-07-28 2002-10-08 Advanced Cardiovascular Systems, Inc. Stent configuration
US6248127B1 (en) 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
US6193744B1 (en) 1998-09-10 2001-02-27 Scimed Life Systems, Inc. Stent configurations
US6342062B1 (en) 1998-09-24 2002-01-29 Scimed Life Systems, Inc. Retrieval devices for vena cava filter
US6363104B1 (en) 1998-10-02 2002-03-26 Ericsson Inc. Method and apparatus for interference cancellation in a rake receiver
US6245104B1 (en) 1999-02-28 2001-06-12 Inflow Dynamics Inc. Method of fabricating a biocompatible stent
US6042597A (en) 1998-10-23 2000-03-28 Scimed Life Systems, Inc. Helical stent design
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
FR2785174A1 (en) 1998-11-03 2000-05-05 Jacques Seguin BODY CONDUIT EXTENSIONER, ESPECIALLY VASCULAR
US6355691B1 (en) 1998-11-12 2002-03-12 Tobias M. Goodman Urushiol therapy of transitional cell carcinoma of the bladder
EP1130996B1 (en) 1998-11-20 2005-04-13 The University of Connecticut Generic integrated implantable potentiostat telemetry unit for electrochemical sensors
CA2353606A1 (en) 1998-12-03 2000-06-08 Boston Scientific Limited Stent having drug crystals thereon
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6147135A (en) 1998-12-31 2000-11-14 Ethicon, Inc. Fabrication of biocompatible polymeric composites
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6171327B1 (en) 1999-02-24 2001-01-09 Scimed Life Systems, Inc. Intravascular filter and method
SE9901002D0 (en) 1999-03-19 1999-03-19 Electrolux Ab Apparatus for cleaning textile articles with a densified liquid processing gas
US6923979B2 (en) 1999-04-27 2005-08-02 Microdose Technologies, Inc. Method for depositing particles onto a substrate using an alternating electric field
US8016873B1 (en) 1999-05-03 2011-09-13 Drasler William J Intravascular hinge stent
JP2000316981A (en) 1999-05-14 2000-11-21 Kawasumi Lab Inc Stent
US6726712B1 (en) 1999-05-14 2004-04-27 Boston Scientific Scimed Prosthesis deployment device with translucent distal end
US6815218B1 (en) 1999-06-09 2004-11-09 Massachusetts Institute Of Technology Methods for manufacturing bioelectronic devices
WO2001014387A1 (en) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6146404A (en) 1999-09-03 2000-11-14 Scimed Life Systems, Inc. Removable thrombus filter
US6610013B1 (en) 1999-10-01 2003-08-26 Life Imaging Systems, Inc. 3D ultrasound-guided intraoperative prostate brachytherapy
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US6537310B1 (en) 1999-11-19 2003-03-25 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal implantable devices and method of making same
US6908624B2 (en) 1999-12-23 2005-06-21 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6572813B1 (en) 2000-01-13 2003-06-03 Advanced Cardiovascular Systems, Inc. Balloon forming process
TWI284048B (en) 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
EP1132058A1 (en) 2000-03-06 2001-09-12 Advanced Laser Applications Holding S.A. Intravascular prothesis
CN2423899Y (en) 2000-05-08 2001-03-21 微创医疗器械(上海)有限公司 Coronary artery stand
EP1280565A2 (en) 2000-05-12 2003-02-05 Advanced Bio Prothestic Surfaces, Ltd. Self-supporting laminated films, structural materials and medical devices
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
US20030077200A1 (en) 2000-07-07 2003-04-24 Craig Charles H. Enhanced radiopaque alloy stent
US20020144757A1 (en) 2000-07-07 2002-10-10 Craig Charles Horace Stainless steel alloy with improved radiopaque characteristics
US7332242B2 (en) 2000-09-01 2008-02-19 Itochu Corporation Lithium-based battery having extensible, ion-impermeable polymer covering on the battery container
AU2001287349B2 (en) 2000-09-01 2006-03-02 Palmaya Pty Ltd Slow release pharmaceutical preparation and method of administering same
US6362718B1 (en) 2000-09-06 2002-03-26 Stephen L. Patrick Motionless electromagnetic generator
US6953560B1 (en) 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US20020111590A1 (en) 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
AU1129902A (en) 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
CA2427795A1 (en) 2000-11-03 2002-05-10 Control Delivery Systems Sustained release device for treating conditions of the joint
US20050084514A1 (en) 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US20040018228A1 (en) 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
WO2002040702A2 (en) 2000-11-09 2002-05-23 Vanderbilt University Methods for the treatment of cancer and other diseases and methods of developing the same
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US7498042B2 (en) 2000-11-30 2009-03-03 Kyoto Medical Planning Co., Ltd. Stent for blood vessel and material for stent for blood vessel
US6913617B1 (en) 2000-12-27 2005-07-05 Advanced Cardiovascular Systems, Inc. Method for creating a textured surface on an implantable medical device
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US6660176B2 (en) 2001-01-24 2003-12-09 Virginia Commonwealth University Molecular imprinting of small particles, and production of small particles from solid state reactants
US20040220660A1 (en) 2001-02-05 2004-11-04 Shanley John F. Bioresorbable stent with beneficial agent reservoirs
DE10106810A1 (en) 2001-02-14 2002-09-05 Siemens Ag Off-grid power supply unit
US6811549B2 (en) 2001-02-16 2004-11-02 William H. Fleming Administration of therapeutic or diagnostic agents using interlabial pad
JP2002239013A (en) 2001-02-21 2002-08-27 Terumo Corp Stent and method of manufacturing for the same
EP1399094A4 (en) 2001-03-16 2004-07-28 Sts Biopolymers Inc Medicated stent having multi-layer polymer coating
US7771468B2 (en) 2001-03-16 2010-08-10 Angiotech Biocoatings Corp. Medicated stent having multi-layer polymer coating
US7282020B2 (en) 2001-04-24 2007-10-16 Microspherix Llc Deflectable implantation device and method of use
US20040022853A1 (en) 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
US6973718B2 (en) 2001-05-30 2005-12-13 Microchips, Inc. Methods for conformal coating and sealing microchip reservoir devices
US20030044514A1 (en) 2001-06-13 2003-03-06 Richard Robert E. Using supercritical fluids to infuse therapeutic on a medical device
US7485113B2 (en) 2001-06-22 2009-02-03 Johns Hopkins University Method for drug delivery through the vitreous humor
US7501157B2 (en) 2001-06-26 2009-03-10 Accelr8 Technology Corporation Hydroxyl functional surface coating
US7015875B2 (en) 2001-06-29 2006-03-21 Novus Partners Llc Dynamic device for billboard advertising
US6585755B2 (en) 2001-06-29 2003-07-01 Advanced Cardiovascular Polymeric stent suitable for imaging by MRI and fluoroscopy
US6967234B2 (en) 2002-12-18 2005-11-22 Ethicon, Inc. Alkyd-lactone copolymers for medical applications
US6743505B2 (en) 2001-07-27 2004-06-01 Ethicon, Inc. Bioabsorbable multifilament yarn and methods of manufacture
US6723913B1 (en) 2001-08-23 2004-04-20 Anthony T. Barbetta Fan cooling of active speakers
US6669980B2 (en) 2001-09-18 2003-12-30 Scimed Life Systems, Inc. Method for spray-coating medical devices
DE50213462D1 (en) 2001-10-15 2009-05-28 Hemoteq Ag COATING OF STENTS TO PREVENT RESTENOSIS
JP2005512995A (en) 2001-11-09 2005-05-12 ファイザー ヘルス アーベー Antimuscarinic and estrogen agonists for treating unstable or overactive bladder
US6517889B1 (en) 2001-11-26 2003-02-11 Swaminathan Jayaraman Process for coating a surface of a stent
US7488313B2 (en) 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
DE10200388A1 (en) 2002-01-08 2003-07-24 Translumina Gmbh coating system
MXPA04006731A (en) 2002-01-10 2004-10-04 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof.
US20030135256A1 (en) 2002-01-14 2003-07-17 Gallagher Brendan P. Stent delivery system
ATE478696T1 (en) 2002-02-15 2010-09-15 Gilead Palo Alto Inc POLYMER COATING FOR MEDICAL DEVICES
US20060093771A1 (en) 2002-02-15 2006-05-04 Frantisek Rypacek Polymer coating for medical devices
WO2003072159A1 (en) 2002-02-28 2003-09-04 Novartis Ag N-{5-[4-(4-methyl-piperazino-methyl)­-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
AU2003228269A1 (en) 2002-03-01 2003-09-16 Mds Proteomics Inc. Phosphorylated proteins and uses related thereto
GB0205868D0 (en) 2002-03-13 2002-04-24 Univ Nottingham Polymer composite with internally distributed deposition matter
US7270675B2 (en) 2002-05-10 2007-09-18 Cordis Corporation Method of forming a tubular membrane on a structural frame
US6669785B2 (en) 2002-05-15 2003-12-30 Micell Technologies, Inc. Methods and compositions for etch cleaning microelectronic substrates in carbon dioxide
DK1507600T3 (en) 2002-05-28 2010-06-07 Battelle Memorial Institute Electrostatic deposition of particles formed by rapid expansion of supercritical liquid solutions
TW200403065A (en) 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters
US7229837B2 (en) 2002-05-30 2007-06-12 Uchicago Argonne, Llc Enhanced photophysics of conjugated polymers
AU2003248624B2 (en) 2002-06-05 2006-04-06 University Of Florida Opthalmic drug delivery system
WO2003106543A1 (en) 2002-06-13 2003-12-24 Kappler, Inc. Microporous membrane with adsorbent multi-functional filler
US6794902B2 (en) 2002-06-14 2004-09-21 Sun Microsystems, Inc. Virtual ground circuit
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US6839913B2 (en) 2002-06-25 2005-01-11 Noble Ideas, Inc. Adjustable garment waistband and method of manufacture
CN100471469C (en) 2002-06-27 2009-03-25 微创医疗器械(上海)有限公司 Drug-eluting stent (DES) with multicoating
WO2004002367A1 (en) 2002-06-27 2004-01-08 Microport Medical (Shanghai) Co., Ltd. Drug eluting stent
US20040013792A1 (en) 2002-07-19 2004-01-22 Samuel Epstein Stent coating holders
US7491233B1 (en) 2002-07-19 2009-02-17 Advanced Cardiovascular Systems Inc. Purified polymers for coatings of implantable medical devices
GB2391439B (en) 2002-07-30 2006-06-21 Wolfson Ltd Bass compressor
US7029495B2 (en) 2002-08-28 2006-04-18 Scimed Life Systems, Inc. Medical devices and methods of making the same
US7060051B2 (en) 2002-09-24 2006-06-13 Scimed Life Systems, Inc. Multi-balloon catheter with hydrogel coating
JP2006500996A (en) 2002-09-26 2006-01-12 エンドバスキュラー デバイセス インコーポレイテッド Apparatus and method for delivering mitomycin via an eluting biocompatible implantable medical device
US6702850B1 (en) 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
US6800663B2 (en) 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
KR100511030B1 (en) 2002-10-21 2005-08-31 한국과학기술연구원 Blood compatible metallic materials and preparation thereof
WO2004043383A2 (en) 2002-11-07 2004-05-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A new target for angiogenesis and anti-angiogenesis therapy
US20050070989A1 (en) 2002-11-13 2005-03-31 Whye-Kei Lye Medical devices having porous layers and methods for making the same
US20040098106A1 (en) 2002-11-14 2004-05-20 Williams Michael S. Intraluminal prostheses and carbon dioxide-assisted methods of impregnating same with pharmacological agents
CA2503388C (en) 2002-11-15 2012-05-15 Synecor, Llc Improved endoprostheses and methods of manufacture
CN1735404A (en) 2002-11-18 2006-02-15 波利梅里斯公司 Medical devices employing novel polymers
JP4371653B2 (en) 2002-11-25 2009-11-25 テルモ株式会社 Implantable medical device
US6790483B2 (en) 2002-12-06 2004-09-14 Eastman Kodak Company Method for producing patterned deposition from compressed fluid
US7094256B1 (en) 2002-12-16 2006-08-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical device containing polycationic peptides
EP1578193A4 (en) 2002-12-23 2011-06-15 Vical Inc Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
US7152452B2 (en) 2002-12-26 2006-12-26 Advanced Cardiovascular Systems, Inc. Assembly for crimping an intraluminal device and method of use
US20040143317A1 (en) 2003-01-17 2004-07-22 Stinson Jonathan S. Medical devices
US7309349B2 (en) * 2003-01-23 2007-12-18 Cordis Corporation Friction reducing lubricant for stent loading and stent delivery systems
JP2004225126A (en) 2003-01-24 2004-08-12 Pioneer Electronic Corp Film deposition mask, and method for manufacturing the same
US20050079199A1 (en) 2003-02-18 2005-04-14 Medtronic, Inc. Porous coatings for drug release from medical devices
AU2004215898A1 (en) 2003-02-26 2004-09-10 Medivas, Llc Bioactive stents and methods for use thereof
US20080051866A1 (en) 2003-02-26 2008-02-28 Chao Chin Chen Drug delivery devices and methods
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7326734B2 (en) 2003-04-01 2008-02-05 The Regents Of The University Of California Treatment of bladder and urinary tract cancers
US20060102871A1 (en) 2003-04-08 2006-05-18 Xingwu Wang Novel composition
US20050208102A1 (en) 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050038498A1 (en) 2003-04-17 2005-02-17 Nanosys, Inc. Medical device applications of nanostructured surfaces
GB0310300D0 (en) 2003-05-06 2003-06-11 Univ Belfast Nanocomposite drug delivery composition
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7524527B2 (en) 2003-05-19 2009-04-28 Boston Scientific Scimed, Inc. Electrostatic coating of a device
US20040236416A1 (en) 2003-05-20 2004-11-25 Robert Falotico Increased biocompatibility of implantable medical devices
US7662864B2 (en) 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
WO2004108274A1 (en) 2003-06-06 2004-12-16 Mitsubishi Chemical Corporation Water-absorbent articles and process for the production thereof
WO2004113429A2 (en) 2003-06-23 2004-12-29 The University Of Chicago Polyolefin nanocomposites
US8399013B2 (en) 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
US7318945B2 (en) 2003-07-09 2008-01-15 Medtronic Vascular, Inc. Laminated drug-polymer coated stent having dipped layers
US7128277B2 (en) 2003-07-29 2006-10-31 Illinois Tool Works Inc. Powder bell with secondary charging electrode
US7056591B1 (en) 2003-07-30 2006-06-06 Advanced Cardiovascular Systems, Inc. Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same
US7169404B2 (en) 2003-07-30 2007-01-30 Advanced Cardiovasular Systems, Inc. Biologically absorbable coatings for implantable devices and methods for fabricating the same
US20050033417A1 (en) 2003-07-31 2005-02-10 John Borges Coating for controlled release of a therapeutic agent
JPWO2005011796A1 (en) 2003-08-05 2006-09-14 株式会社カネカ Indwelling stent
RS51934B (en) 2003-08-08 2012-02-29 Biovail Laboratories International Srl. Modified-release tablet of bupropion hydrochloride
JP2007502281A (en) 2003-08-13 2007-02-08 メドトロニック・インコーポレーテッド Active agent release system, medical device and method comprising a miscible polymer formulation
US7204560B2 (en) 2003-08-15 2007-04-17 Sandvik Intellectual Property Ab Rotary cutting bit with material-deflecting ledge
JP4732346B2 (en) 2003-08-19 2011-07-27 バイエル・マテリアルサイエンス・アクチェンゲゼルシャフト Polymeric drug elution system for medical devices
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US8801692B2 (en) 2003-09-24 2014-08-12 Medtronic Vascular, Inc. Gradient coated stent and method of fabrication
US20050070990A1 (en) 2003-09-26 2005-03-31 Stinson Jonathan S. Medical devices and methods of making same
US7744645B2 (en) 2003-09-29 2010-06-29 Medtronic Vascular, Inc. Laminated drug-polymer coated stent with dipped and cured layers
US7618647B2 (en) 2003-10-03 2009-11-17 Boston Scientific Scimed, Inc. Using bucky paper as a therapeutic aid in medical applications
US7329383B2 (en) 2003-10-22 2008-02-12 Boston Scientific Scimed, Inc. Alloy compositions and devices including the compositions
JP2007509220A (en) 2003-10-23 2007-04-12 ユニバーシテイ・オブ・ノツテインガム Preparation of active polymer extrudates
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
JP4618997B2 (en) 2003-12-09 2011-01-26 テルモ株式会社 Stent and manufacturing method thereof
ATE377101T1 (en) 2003-12-16 2007-11-15 Cytec Surface Specialties Sa METHOD FOR APPLYING A COATING TO A WOUND METAL SHEET
US20050131513A1 (en) 2003-12-16 2005-06-16 Cook Incorporated Stent catheter with a permanently affixed conductor
EP1699503B8 (en) 2003-12-24 2012-11-07 Novartis AG Devices coated with PEC polymers
US20050268573A1 (en) 2004-01-20 2005-12-08 Avantec Vascular Corporation Package of sensitive articles
US7306677B2 (en) 2004-01-30 2007-12-11 Boston Scientific Corporation Clamping fixture for coating stents, system using the fixture, and method of using the fixture
GB2411078B (en) 2004-02-10 2009-02-04 Samsung Electronics Co Ltd Mobile communications
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US7550444B2 (en) 2004-03-26 2009-06-23 Surmodics, Inc. Composition and method for preparing biocompatible surfaces
CN1964748A (en) 2004-04-06 2007-05-16 苏莫迪克斯公司 Coating compositions for bioactive agents
US20050288481A1 (en) 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions
US7820732B2 (en) 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices
EP1744795A1 (en) 2004-05-14 2007-01-24 Becton, Dickinson and Company Articles having bioactive surfaces and solvent-free methods of preparation thereof
WO2005117942A2 (en) 2004-05-14 2005-12-15 The Regents Of The University Of Michigan Methods for encapsulation of biomacromolecules in polymers
US7682656B2 (en) 2004-06-14 2010-03-23 Agruim Inc. Process and apparatus for producing a coated product
US7976557B2 (en) 2004-06-23 2011-07-12 Boston Scientific Scimed, Inc. Cutting balloon and process
CA2511212A1 (en) 2004-07-02 2006-01-02 Henkel Kommanditgesellschaft Auf Aktien Surface conditioner for powder coating systems
JP2008506703A (en) 2004-07-14 2008-03-06 ユニバーシティ オブ ユタ リサーチ ファウンデーション Netrin-related compounds and uses
US8541078B2 (en) 2004-08-06 2013-09-24 Societe Bic Fuel supplies for fuel cells
WO2006023530A2 (en) 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
US7425368B2 (en) 2004-08-20 2008-09-16 Massachusetts Institute Of Technology Filler-enhanced polymeric fibers with improved mechanical properties and method for making
US8119153B2 (en) 2004-08-26 2012-02-21 Boston Scientific Scimed, Inc. Stents with drug eluting coatings
EP1792582B1 (en) 2004-09-08 2018-04-04 Kaneka Corporation Indwelling stent
EP1787676A4 (en) 2004-09-08 2012-06-20 Kaneka Corp Stent for placement in body
US8001922B2 (en) 2004-09-28 2011-08-23 Atrium Medical Corporation Application of a coating on a medical device
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US20060093643A1 (en) 2004-11-04 2006-05-04 Stenzel Eric B Medical device for delivering therapeutic agents over different time periods
US7455658B2 (en) 2004-11-10 2008-11-25 Samw Hong Jen Wang Fluid dispensing or feeding device
US7455688B2 (en) 2004-11-12 2008-11-25 Con Interventional Systems, Inc. Ostial stent
EP1819373A2 (en) 2004-12-07 2007-08-22 SurModics, Inc. Coatings with crystallized active agent(s)
US7632307B2 (en) 2004-12-16 2009-12-15 Advanced Cardiovascular Systems, Inc. Abluminal, multilayer coating constructs for drug-delivery stents
US7727273B2 (en) 2005-01-13 2010-06-01 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US7772352B2 (en) 2005-01-28 2010-08-10 Bezwada Biomedical Llc Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices
WO2006110197A2 (en) 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
BRPI0609012A2 (en) 2005-03-14 2016-11-29 3M Innovative Properties Co "Medical formulation, metered dose inhaler, powder, dry powder inhaler, and methods of stabilizing a medicinal formulation in a drug delivery system and treating an animal from a condition capable of being treated by a drug."
US7837726B2 (en) 2005-03-14 2010-11-23 Abbott Laboratories Visible endoprosthesis
CN101175481A (en) 2005-03-17 2008-05-07 伊兰制药国际有限公司 Injectable compositions of nanoparticulate immunosuppressive compounds
US20090216317A1 (en) 2005-03-23 2009-08-27 Cromack Keith R Delivery of Highly Lipophilic Agents Via Medical Devices
US8628565B2 (en) 2005-04-13 2014-01-14 Abbott Cardiovascular Systems Inc. Intravascular stent
KR101406415B1 (en) 2005-07-15 2014-06-19 미셀 테크놀로지즈, 인코포레이티드 Polymer coatings containing drug powder of controlled morphology
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US20070026042A1 (en) 2005-07-29 2007-02-01 Narayanan Pallasssana V System for treating aneurysmal disease
US8377462B2 (en) 2005-07-29 2013-02-19 Advanced Cardiovascular Systems, Inc. PEA-TEMPO/PEA-BZ coatings for controlled delivery of drug from implantable medical devices
CA2617190C (en) 2005-08-03 2017-07-18 The University Of Western Ontario Direct coating solid dosage forms using powdered materials
ATE417440T1 (en) 2005-08-05 2008-12-15 Telecom Italia Spa METHOD FOR ESTABLISHING A CONNECTION IN A COMMUNICATIONS NETWORK
WO2007017707A1 (en) 2005-08-11 2007-02-15 Hilary Nwokeabia The slanting toothbrush
WO2007022055A1 (en) 2005-08-12 2007-02-22 Massicotte J Mathieu Method and device for extracting objects from the body
US20070043434A1 (en) 2005-08-18 2007-02-22 David Meerkin Biodegradable endovascular stent using stereocomplexation of polymers
EP1764116A1 (en) 2005-09-16 2007-03-21 Debiotech S.A. Porous coating process using colloidal particles
US7935379B2 (en) 2005-11-14 2011-05-03 Boston Scientific Scimed, Inc. Coated and imprinted medical devices and methods of making the same
MY162248A (en) 2005-12-09 2017-05-31 Dsm Ip Assets Bv Hydrophilic coating
US20070148251A1 (en) 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US8834912B2 (en) 2005-12-30 2014-09-16 Boston Scientific Scimed, Inc. Medical devices having multiple charged layers
US7919108B2 (en) 2006-03-10 2011-04-05 Cook Incorporated Taxane coatings for implantable medical devices
US20080286325A1 (en) 2006-01-05 2008-11-20 Med Institute, Inc. Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
CN103356309B (en) 2006-01-23 2015-11-25 史密夫和内修有限公司 Patellar components
AU2007212697B2 (en) 2006-01-27 2012-08-30 Cook Medical Technologies Llc Device with nanocomposite coating for controlled drug release
WO2007089259A1 (en) 2006-02-02 2007-08-09 The Johns Hopkins University Therapeutic electrospun fiber compositions
JP4297221B2 (en) 2006-02-15 2009-07-15 株式会社ホソカワ粉体技術研究所 Method for producing drug-eluting stent
US20070196242A1 (en) 2006-02-23 2007-08-23 Agamatrix, Inc. Used test strip storage container
US20070200268A1 (en) 2006-02-24 2007-08-30 Vipul Dave Implantable device prepared from solution processing
US8500772B2 (en) 2006-03-20 2013-08-06 Cook Medical Technologies Llc Distal protection device
US20070225795A1 (en) 2006-03-24 2007-09-27 Juan Granada Composite vascular prosthesis
US7955383B2 (en) 2006-04-25 2011-06-07 Medtronics Vascular, Inc. Laminated implantable medical device having a metallic coating
WO2007127363A2 (en) 2006-04-26 2007-11-08 Micell Technologies, Inc. Coatings containing multiple drugs
US7691400B2 (en) 2006-05-05 2010-04-06 Medtronic Vascular, Inc. Medical device having coating with zeolite drug reservoirs
US20080279909A1 (en) 2006-05-12 2008-11-13 Cleek Robert L Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization
US7959940B2 (en) 2006-05-30 2011-06-14 Advanced Cardiovascular Systems, Inc. Polymer-bioceramic composite implantable medical devices
US20070281117A1 (en) 2006-06-02 2007-12-06 Xtent, Inc. Use of plasma in formation of biodegradable stent coating
BRPI0603437A2 (en) 2006-06-06 2010-07-06 Luiz Gonzaga Granja Jr extraluminal stent anastomosis prosthesis
US20080124372A1 (en) 2006-06-06 2008-05-29 Hossainy Syed F A Morphology profiles for control of agent release rates from polymer matrices
US8535372B1 (en) 2006-06-16 2013-09-17 Abbott Cardiovascular Systems Inc. Bioabsorbable stent with prohealing layer
WO2008008291A2 (en) 2006-07-13 2008-01-17 Icon Medical Corp. Stent
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
WO2008024626A2 (en) 2006-08-21 2008-02-28 Innovational Holdings Llc Bioresorbable stent with extended in vivo release of anti-restenotic agent
US20080065192A1 (en) 2006-09-13 2008-03-13 Medtronic Vascular, Inc. Compliance Graded Stent
CN101557814B (en) 2006-09-13 2015-05-20 万能医药公司 Macrocyclic lactone compounds and methods for their use
WO2008033603A2 (en) 2006-09-15 2008-03-20 Boston Scientific Limited Medical devices having alloy compositions
JP2010503486A (en) 2006-09-18 2010-02-04 ボストン サイエンティフィック リミテッド Endoprosthesis
US8636767B2 (en) 2006-10-02 2014-01-28 Micell Technologies, Inc. Surgical sutures having increased strength
EP1913960A1 (en) 2006-10-19 2008-04-23 Albert Schömig Coated implant
EP1916006A1 (en) 2006-10-19 2008-04-30 Albert Schömig Implant coated with a wax or a resin
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
US20080098178A1 (en) 2006-10-23 2008-04-24 Veazey Judson E Data storage on a switching system coupling multiple processors of a computer system
CA2667228C (en) 2006-10-23 2015-07-14 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
EP2101779A1 (en) 2006-12-13 2009-09-23 Angiotech Pharmaceuticals, Inc. Medical implants with a combination of compounds
WO2008086369A1 (en) 2007-01-08 2008-07-17 Micell Technologies, Inc. Stents having biodegradable layers
US20130150943A1 (en) 2007-01-19 2013-06-13 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
KR20120106880A (en) 2007-01-21 2012-09-26 헤모텍 아게 Medical product for treating stenosis of body passages and for preventing threatening restenosis
US7745566B2 (en) 2007-01-23 2010-06-29 Ferro Corporation Methods for the purification of polymers
US8295565B2 (en) 2007-03-16 2012-10-23 Sti Medical Systems, Llc Method of image quality assessment to produce standardized imaging data
US7815962B2 (en) 2007-03-22 2010-10-19 Medtronic Vascular, Inc. Coated stent with evenly distributed therapeutic agent
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
NZ580469A (en) 2007-04-17 2012-05-25 Micell Technologies Inc Coronary stents having biodegradable layers
WO2008137148A2 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
WO2008144600A1 (en) 2007-05-17 2008-11-27 Prescient Medical, Inc. Multi-channel fiber optic spectroscopy systems employing integrated optics modules
GB0709517D0 (en) 2007-05-17 2007-06-27 Queen Mary & Westfield College An electrostatic spraying device and a method of electrostatic spraying
WO2008148013A1 (en) 2007-05-25 2008-12-04 Micell Technologies, Inc. Polymer films for medical device coating
US7922760B2 (en) 2007-05-29 2011-04-12 Abbott Cardiovascular Systems Inc. In situ trapping and delivery of agent by a stent having trans-strut depots
US8109904B1 (en) 2007-06-25 2012-02-07 Abbott Cardiovascular Systems Inc. Drug delivery medical devices
US20090068266A1 (en) 2007-09-11 2009-03-12 Raheja Praveen Sirolimus having specific particle size and pharmaceutical compositions thereof
US20090076446A1 (en) 2007-09-14 2009-03-19 Quest Medical, Inc. Adjustable catheter for dilation in the ear, nose or throat
WO2009039553A1 (en) 2007-09-27 2009-04-02 The Walter And Eliza Hall Institute Of Medical Research Benzothiazole compounds
US8709071B1 (en) 2007-09-28 2014-04-29 Abbott Cardiovascular Systems Inc. Stent with preferential coating
JP5114788B2 (en) 2007-09-28 2013-01-09 三菱重工業株式会社 Lithium secondary battery
EP2214646B1 (en) 2007-10-05 2021-06-23 Wayne State University Dendrimers for sustained release of compounds
US20090105687A1 (en) 2007-10-05 2009-04-23 Angioscore, Inc. Scoring catheter with drug delivery membrane
WO2009051780A1 (en) 2007-10-19 2009-04-23 Micell Technologies, Inc. Drug coated stents
WO2009058098A1 (en) 2007-10-30 2009-05-07 Nanyang Technological University A non-biodegradable stent comprising a biodegradable coating and method of coating the same
US20090111787A1 (en) 2007-10-31 2009-04-30 Florencia Lim Polymer blends for drug delivery stent matrix with improved thermal stability
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
CN101161300B (en) 2007-11-27 2011-03-16 北京美中双和医疗器械有限公司 Arsenic trioxide medicament elution bracket and its preparation method
US20090202609A1 (en) 2008-01-06 2009-08-13 Keough Steven J Medical device with coating composition
WO2009096822A1 (en) 2008-01-30 2009-08-06 Micromuscle Ab Drug delivery devices and methods and applications thereof
US20100042206A1 (en) 2008-03-04 2010-02-18 Icon Medical Corp. Bioabsorbable coatings for medical devices
EP2262566A1 (en) 2008-03-06 2010-12-22 Boston Scientific Scimed, Inc. Balloon catheter devices with folded balloons
KR20100132486A (en) 2008-03-12 2010-12-17 안게스 엠지 인코포레이티드 Drug elution-type catheter and method for manufacturing the drug elution-type catheter
US8951545B2 (en) 2008-03-28 2015-02-10 Surmodics, Inc. Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery
JP5608160B2 (en) 2008-04-17 2014-10-15 ミセル テクノロジーズ、インコーポレイテッド Stent with bioabsorbable layer
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US20110143429A1 (en) 2008-04-30 2011-06-16 Iksoo Chun Tissue engineered blood vessels
EP2293357B1 (en) 2008-05-08 2014-12-10 Nippon Steel & Sumikin Chemical Co., Ltd. Compound for organic electroluminescent device and organic electroluminescent device
US8298607B2 (en) 2008-05-15 2012-10-30 Abbott Cardiovascular Systems Inc. Method for electrostatic coating of a medical device
US7865562B2 (en) 2008-05-20 2011-01-04 International Business Machines Corporation Selecting email signatures
EP2131614B1 (en) 2008-05-30 2014-01-01 Alcatel Lucent Method for transmitting broadcast services in a radiocommunication cellular network through a femto base station, as well as corresponding femto base station
US20090297578A1 (en) 2008-06-03 2009-12-03 Trollsas Mikael O Biosoluble coating comprising anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
RU2508093C2 (en) 2008-07-01 2014-02-27 Нитто Денко Корпорейшн Pharmaceutical composition containing coated microparticles
US7770466B2 (en) 2008-07-02 2010-08-10 Abbott Cardiovascular Systems Inc. Method for measuring stent dislodgement force
JP4557061B2 (en) 2008-07-11 2010-10-06 トヨタ自動車株式会社 Hybrid vehicle and control method thereof
CA2946195A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
JP2010052503A (en) 2008-08-27 2010-03-11 Kawano Terukazu Engine for vessel
US20100055145A1 (en) 2008-08-29 2010-03-04 Biosensors International Group Stent coatings for reducing late stent thrombosis
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8367090B2 (en) 2008-09-05 2013-02-05 Abbott Cardiovascular Systems Inc. Coating on a balloon comprising a polymer and a drug
CA2734414A1 (en) 2008-09-19 2010-03-25 Innovative Surface Technologies, Inc. Drug eluting superhydrophobic coatings
US20110172763A1 (en) 2008-09-29 2011-07-14 Robert Ndondo-Lay Matrix Coated Stent
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
CA2743491C (en) 2008-11-11 2016-10-11 Zelton Dave Sharp Inhibition of mammalian target of rapamycin
WO2010059783A2 (en) 2008-11-21 2010-05-27 Lifecell Corporation Reinforced biologic material
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
EP2384206B1 (en) 2008-12-26 2018-08-01 Battelle Memorial Institute Medical implants and methods of making medical implants
US20120231037A1 (en) 2009-02-02 2012-09-13 Yissum Research Development Companyof the Hebrew U Crystalline drug-containing coatings
US9572692B2 (en) 2009-02-02 2017-02-21 Abbott Cardiovascular Systems Inc. Bioabsorbable stent that modulates plaque geometric morphology and chemical composition
US20100198330A1 (en) 2009-02-02 2010-08-05 Hossainy Syed F A Bioabsorbable Stent And Treatment That Elicits Time-Varying Host-Material Response
WO2010111232A2 (en) 2009-03-23 2010-09-30 Micell Technologies, Inc. Drug delivery medical device
US20100256746A1 (en) 2009-03-23 2010-10-07 Micell Technologies, Inc. Biodegradable polymers
EP2410954A4 (en) 2009-03-23 2014-03-05 Micell Technologies Inc Peripheral stents having layers
EP2413847A4 (en) 2009-04-01 2013-11-27 Micell Technologies Inc Coated stents
US20110301697A1 (en) 2009-04-10 2011-12-08 Hemoteq Ag Manufacture, method and use of drug-eluting medical devices for permanently keeping blood vessels open
US9492587B2 (en) 2009-04-13 2016-11-15 Abbott Cardiovascular Systems Inc. Stent made from an ultra high molecular weight bioabsorbable polymer with high fatigue and fracture resistance
EP3366326A1 (en) 2009-04-17 2018-08-29 Micell Technologies, Inc. Stents having controlled elution
US20100285085A1 (en) 2009-05-07 2010-11-11 Abbott Cardiovascular Systems Inc. Balloon coating with drug transfer control via coating thickness
EP4289416A3 (en) 2009-05-18 2024-01-03 Dose Medical Corporation Drug eluting ocular implant
WO2010136604A1 (en) 2009-05-29 2010-12-02 Dsm Ip Assets B.V. Transfer matrix for transferring a bioactive agent to body tissue
EP2266507B1 (en) 2009-06-22 2015-07-29 Biotronik VI Patent AG Stent having improved stent design
US9327060B2 (en) 2009-07-09 2016-05-03 CARDINAL HEALTH SWITZERLAND 515 GmbH Rapamycin reservoir eluting stent
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc Drug delivery medical device
US8039147B2 (en) 2009-08-27 2011-10-18 Sb Limotive Co., Ltd. Rechargeable secondary battery having improved safety against puncture and collapse
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
CA3014008A1 (en) 2010-03-25 2011-09-29 Lutonix, Inc. Drug releasing coatings for medical devices
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
WO2011123798A2 (en) 2010-04-01 2011-10-06 The Johns Hopkins University Three-dimensional scaffolds, methods for fabricating the same, and methods of treating a peripheral nerve or spinal or spinal cord injury
CA2794704C (en) 2010-04-16 2019-09-17 Micell Technologies, Inc. Stents having controlled elution
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US10189773B2 (en) 2010-05-07 2019-01-29 Medicus Biosciences, Llc In-vivo gelling pharmaceutical pre-formulation
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
CA2810842C (en) 2010-09-09 2018-06-26 Micell Technologies, Inc. Macrolide dosage forms
US20120150275A1 (en) 2010-12-10 2012-06-14 Micropen Technologies Corporation Stents and methods of making stents
US8974622B2 (en) 2010-12-28 2015-03-10 Boston Scientific Scimed, Inc. Composite ePTFE-silicone covering for stent
US20120177742A1 (en) 2010-12-30 2012-07-12 Micell Technologies, Inc. Nanoparticle and surface-modified particulate coatings, coated balloons, and methods therefore
WO2012097381A1 (en) 2011-01-14 2012-07-19 Biomerix Corporation At least partially resorbable reticulated elastomeric matrix elements and methods of making same
WO2012142319A1 (en) 2011-04-13 2012-10-18 Micell Technologies, Inc. Stents having controlled elution
TW201311226A (en) 2011-05-06 2013-03-16 Ind Tech Res Inst Method for manufacturing bioabsorbable stents
US9446172B2 (en) 2011-05-10 2016-09-20 Abbott Cardiovascular Systems Inc. Modification of bioabsorbable stent to reduce thrombogenecity
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
WO2013003644A1 (en) 2011-06-30 2013-01-03 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US20140257465A1 (en) 2011-08-12 2014-09-11 Micell Technologies, Inc. Stents having controlled elution
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN104093445B (en) 2011-10-18 2016-09-07 米歇尔技术公司 drug delivery medical device
WO2013177211A1 (en) 2012-05-21 2013-11-28 Micell Technologies, Inc. Safe drug eluting stent with absorbable coating
JP2013153822A (en) 2012-01-27 2013-08-15 Terumo Corp In-vivo indwelling stent and living organ dilator
US9090029B2 (en) 2012-02-06 2015-07-28 Warsaw Orthopedic, Inc. Pultrusion process for preparing composites having low percentage of fibers and articles made from same
US8859088B2 (en) 2012-04-16 2014-10-14 Auburn University Minimal weight composites using open structure
WO2013173657A1 (en) 2012-05-16 2013-11-21 Micell Technologies, Inc. Low burst sustained release lipophilic and biologic agent compositions
KR101231197B1 (en) 2012-09-20 2013-02-07 썬텍 주식회사 Polymeric stent
JP2015533305A (en) 2012-10-18 2015-11-24 ミセル テクノロジーズ,インク. Drug delivery medical device
JP6330024B2 (en) 2013-03-12 2018-05-23 マイセル・テクノロジーズ,インコーポレイテッド Bioabsorbable biomedical implant
JP2016519965A (en) 2013-05-15 2016-07-11 マイセル・テクノロジーズ,インコーポレイテッド Bioabsorbable biomedical implant

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3087860A (en) * 1958-12-19 1963-04-30 Abbott Lab Method of prolonging release of drug from a precompressed solid carrier
US3087660A (en) * 1962-07-24 1963-04-30 Yankee Plasties Inc Two-step garment hanger
US4326532A (en) * 1980-10-06 1982-04-27 Minnesota Mining And Manufacturing Company Antithrombogenic articles
US4733665B1 (en) * 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US6409716B1 (en) * 1989-12-15 2002-06-25 Scimed Life Systems, Inc. Drug delivery
US5569463A (en) * 1990-05-17 1996-10-29 Harbor Medical Devices, Inc. Medical device polymer
US6524698B1 (en) * 1990-09-27 2003-02-25 Helmuth Schmoock Fluid impermeable foil
US5158986A (en) * 1991-04-05 1992-10-27 Massachusetts Institute Of Technology Microcellular thermoplastic foamed with supercritical fluid
US5356433A (en) * 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
US5243023A (en) * 1991-08-28 1993-09-07 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polyimides containing amide and perfluoroisopropylidene connecting groups
US5342621A (en) * 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US5340614A (en) * 1993-02-11 1994-08-23 Minnesota Mining And Manufacturing Company Methods of polymer impregnation
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5948020A (en) * 1995-05-01 1999-09-07 Sam Yang Co., Ltd. Implantable bioresorbable membrane and method for the preparation thereof
US5873904A (en) * 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US5824049A (en) * 1995-06-07 1998-10-20 Med Institute, Inc. Coated implantable medical device
US5811032A (en) * 1995-09-19 1998-09-22 Mitsubishi Gas Chemical Company, Inc. Biodegradable water-soluble polymer
US6461644B1 (en) * 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US6884377B1 (en) * 1996-08-27 2005-04-26 Trexel, Inc. Method and apparatus for microcellular polymer extrusion
US20050003074A1 (en) * 1996-11-13 2005-01-06 Phoqus Pharmaceuticals Limited Method and apparatus for the coating of substrates for pharmaceutical use
US6517860B1 (en) * 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
US6884823B1 (en) * 1997-01-16 2005-04-26 Trexel, Inc. Injection molding of polymeric material
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6414050B1 (en) * 1997-05-10 2002-07-02 University Of Nottingham Biofunctional polymers prepared in supercritical fluid
US7378105B2 (en) * 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US6736996B1 (en) * 1997-10-10 2004-05-18 North Carolina State University Compositions for protecting civil infrastructure
US5957975A (en) * 1997-12-15 1999-09-28 The Cleveland Clinic Foundation Stent having a programmed pattern of in vivo degradation
US6838089B1 (en) * 1998-04-14 2005-01-04 Astrazeneca Ab Antigen delivery system and method of production
US6190699B1 (en) * 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
US6939569B1 (en) * 1998-06-19 2005-09-06 Oxibio, Inc. Medical device having anti-infective and contraceptive properties
US6372246B1 (en) * 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6448315B1 (en) * 1999-02-17 2002-09-10 Bone Support Ab Method for the preparation of UHMWPE doped with an antioxidant and an implant made thereof
US20040106982A1 (en) * 1999-03-16 2004-06-03 Jalisi Marc M. Multilayer stent
US6364903B2 (en) * 1999-03-19 2002-04-02 Meadox Medicals, Inc. Polymer coated stent
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6710059B1 (en) * 1999-07-06 2004-03-23 Endorecherche, Inc. Methods of treating and/or suppressing weight gain
US20020133072A1 (en) * 1999-09-10 2002-09-19 Guo-Bin Wang Graft polymerization of substrate surfaces
US6755871B2 (en) * 1999-10-15 2004-06-29 R.R. Street & Co. Inc. Cleaning system utilizing an organic cleaning solvent and a pressurized fluid solvent
US6767558B2 (en) * 2000-03-10 2004-07-27 Pfizer Inc. Inhibiting oxidative degradation of pharmaceutical formulations
US20070123977A1 (en) * 2000-03-15 2007-05-31 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US6627246B2 (en) * 2000-05-16 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Process for coating stents and other medical devices using super-critical carbon dioxide
US6521258B1 (en) * 2000-09-08 2003-02-18 Ferro Corporation Polymer matrices prepared by supercritical fluid processing techniques
US6506213B1 (en) * 2000-09-08 2003-01-14 Ferro Corporation Manufacturing orthopedic parts using supercritical fluid processing techniques
US20060222756A1 (en) * 2000-09-29 2006-10-05 Cordis Corporation Medical devices, drug coatings and methods of maintaining the drug coatings thereon
US20050004661A1 (en) * 2001-01-11 2005-01-06 Lewis Andrew L Stens with drug-containing amphiphilic polymer coating
US6838528B2 (en) * 2001-01-19 2005-01-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
US6897205B2 (en) * 2001-01-31 2005-05-24 Roehm Gmbh & Co. Kg Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
US6905555B2 (en) * 2001-02-15 2005-06-14 Micell Technologies, Inc. Methods for transferring supercritical fluids in microelectronic and other industrial processes
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
US20030180376A1 (en) * 2001-03-02 2003-09-25 Dalal Paresh S. Porous beta-tricalcium phosphate granules and methods for producing same
US20030143315A1 (en) * 2001-05-16 2003-07-31 Pui David Y H Coating medical devices
US7163715B1 (en) * 2001-06-12 2007-01-16 Advanced Cardiovascular Systems, Inc. Spray processing of porous medical devices
US20030125800A1 (en) * 2001-11-05 2003-07-03 Shulze John E. Drug-delivery endovascular stent and method for treating restenosis
US20030088307A1 (en) * 2001-11-05 2003-05-08 Shulze John E. Potent coatings for stents
US6868123B2 (en) * 2001-12-07 2005-03-15 Motorola, Inc. Programmable motion estimation module with vector array unit
US6837611B2 (en) * 2001-12-28 2005-01-04 Metal Industries Research & Development Centre Fluid driven agitator used in densified gas cleaning system
US20060121089A1 (en) * 2002-03-20 2006-06-08 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US20030185964A1 (en) * 2002-03-28 2003-10-02 Jan Weber Method for spray-coating a medical device having a tubular wall such as a stent
US20030204238A1 (en) * 2002-04-26 2003-10-30 Eugene Tedeschi Coated stent with crimpable coating
US6780475B2 (en) * 2002-05-28 2004-08-24 Battelle Memorial Institute Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions
US6756084B2 (en) * 2002-05-28 2004-06-29 Battelle Memorial Institute Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions
US6749902B2 (en) * 2002-05-28 2004-06-15 Battelle Memorial Institute Methods for producing films using supercritical fluid
US20040126542A1 (en) * 2002-07-29 2004-07-01 Nitto Denko Corporation Pressure-sensitive adhesive tape or sheet
US20050019747A1 (en) * 2002-08-07 2005-01-27 Anderson Daniel G. Nanoliter-scale synthesis of arrayed biomaterials and screening thereof
US20030031699A1 (en) * 2002-09-30 2003-02-13 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
US20050010275A1 (en) * 2002-10-11 2005-01-13 Sahatjian Ronald A. Implantable medical devices
US20060193890A1 (en) * 2002-11-13 2006-08-31 Owens Gary K Method for loading nanoporous layers with therapeutic agent
US20060193886A1 (en) * 2002-11-13 2006-08-31 Owens Gary K Medical devices with nanoporous layers and topcoats
US20040193262A1 (en) * 2003-03-29 2004-09-30 Shadduck John H. Implants for treating ocular hypertension, methods of use and methods of fabrication
US20040193177A1 (en) * 2003-03-31 2004-09-30 Houghton Michael J. Modified delivery device for coated medical devices
US20050191491A1 (en) * 2003-04-08 2005-09-01 Yulu Wang Polymer coating/encapsulation of nanoparticles using a supercritical antisolvent process
US20050216075A1 (en) * 2003-04-08 2005-09-29 Xingwu Wang Materials and devices of enhanced electromagnetic transparency
US20050196424A1 (en) * 2003-05-02 2005-09-08 Chappa Ralph A. Medical devices and methods for producing the same
US20080118543A1 (en) * 2003-05-08 2008-05-22 Advanced Cardiovascular Systems, Inc. Stent Coatings comprising hydrophilic additives
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20050015046A1 (en) * 2003-07-18 2005-01-20 Scimed Life Systems, Inc. Medical devices and processes for preparing same
US20050049694A1 (en) * 2003-08-07 2005-03-03 Medtronic Ave. Extrusion process for coating stents
US20050177223A1 (en) * 2003-09-18 2005-08-11 Palmaz Julio C. Medical devices having MEMs functionality and methods of making same
US20050069630A1 (en) * 2003-09-30 2005-03-31 Advanced Cardiovascular Systems, Inc. Stent mandrel fixture and method for selectively coating surfaces of a stent
US20050079274A1 (en) * 2003-10-14 2005-04-14 Maria Palasis Method for coating multiple stents
US20050147734A1 (en) * 2004-01-07 2005-07-07 Jan Seppala Method and system for coating tubular medical devices
US20050175772A1 (en) * 2004-02-10 2005-08-11 Robert Worsham Apparatus and method for electrostatic spray coating of medical devices
US20050238829A1 (en) * 2004-04-22 2005-10-27 John Motherwell Differentially coated medical devices, system for differentially coating medical devices, and coating method
US20060020325A1 (en) * 2004-07-26 2006-01-26 Robert Burgermeister Material for high strength, controlled recoil stent
US20060094744A1 (en) * 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US20060134211A1 (en) * 2004-12-16 2006-06-22 Miv Therapeutics Inc. Multi-layer drug delivery device and method of manufacturing same
US20060136041A1 (en) * 2004-12-17 2006-06-22 Schmid Eric V Slide-and-lock stent
US20060198868A1 (en) * 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
US20070196423A1 (en) * 2005-11-21 2007-08-23 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
US20070203569A1 (en) * 2006-02-24 2007-08-30 Robert Burgermeister Implantable device formed from polymer blends having modified molecular structures
US20080075753A1 (en) * 2006-09-25 2008-03-27 Chappa Ralph A Multi-layered coatings and methods for controlling elution of active agents
US20080255510A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080213464A1 (en) * 2007-01-03 2008-09-04 Boston Scientific Scimed, Inc. Methods of applying coating to the inside surface of a stent
US20080206304A1 (en) * 2007-02-27 2008-08-28 Boston Scientific Scimed, Inc. Medical devices having polymeric regions based on styrene-isobutylene copolymers
US20090105809A1 (en) * 2007-10-19 2009-04-23 Lee Michael J Implantable and lumen-supporting stents and related methods of manufacture and use

Cited By (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835396B2 (en) 2005-07-15 2020-11-17 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US20090123515A1 (en) * 2005-07-15 2009-05-14 Doug Taylor Polymer coatings containing drug powder of controlled morphology
US10898353B2 (en) 2005-07-15 2021-01-26 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US8298565B2 (en) 2005-07-15 2012-10-30 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US9827117B2 (en) 2005-07-15 2017-11-28 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US8758429B2 (en) 2005-07-15 2014-06-24 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US11911301B2 (en) 2005-07-15 2024-02-27 Micell Medtech Inc. Polymer coatings containing drug powder of controlled morphology
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US9415142B2 (en) 2006-04-26 2016-08-16 Micell Technologies, Inc. Coatings containing multiple drugs
US11850333B2 (en) 2006-04-26 2023-12-26 Micell Medtech Inc. Coatings containing multiple drugs
US11007307B2 (en) 2006-04-26 2021-05-18 Micell Technologies, Inc. Coatings containing multiple drugs
US9737645B2 (en) 2006-04-26 2017-08-22 Micell Technologies, Inc. Coatings containing multiple drugs
US20090186069A1 (en) * 2006-04-26 2009-07-23 Micell Technologies, Inc. Coatings Containing Multiple Drugs
US20100030261A1 (en) * 2006-10-02 2010-02-04 Micell Technologies, Inc. Surgical Sutures Having Increased Strength
US8636767B2 (en) 2006-10-02 2014-01-28 Micell Technologies, Inc. Surgical sutures having increased strength
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US20080095919A1 (en) * 2006-10-23 2008-04-24 Mcclain James B Holder For Electrically Charging A Substrate During Coating
US10617795B2 (en) 2007-01-08 2020-04-14 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US20100063580A1 (en) * 2007-01-08 2010-03-11 Mcclain James B Stents having biodegradable layers
US9737642B2 (en) * 2007-01-08 2017-08-22 Micell Technologies, Inc. Stents having biodegradable layers
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US20100211164A1 (en) * 2007-04-17 2010-08-19 Mcclain James B Stents having biodegradable layers
US9486338B2 (en) 2007-04-17 2016-11-08 Micell Technologies, Inc. Stents having controlled elution
US9775729B2 (en) 2007-04-17 2017-10-03 Micell Technologies, Inc. Stents having controlled elution
US20100272778A1 (en) * 2007-04-17 2010-10-28 Micell Technologies, Inc. Stents having controlled elution
US20100228348A1 (en) * 2007-05-25 2010-09-09 Micell Technologies, Inc. Polymer Films for Medical Device Coating
US8900651B2 (en) 2007-05-25 2014-12-02 Micell Technologies, Inc. Polymer films for medical device coating
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
US9789233B2 (en) 2008-04-17 2017-10-17 Micell Technologies, Inc. Stents having bioabsorbable layers
US10350333B2 (en) 2008-04-17 2019-07-16 Micell Technologies, Inc. Stents having bioabsorable layers
US20090292351A1 (en) * 2008-04-17 2009-11-26 Micell Technologies, Inc. Stents having bioabsorbable layers
US10350391B2 (en) 2008-07-17 2019-07-16 Micell Technologies, Inc. Drug delivery medical device
US20100015200A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug Delivery Medical Device
US9981071B2 (en) 2008-07-17 2018-05-29 Micell Technologies, Inc. Drug delivery medical device
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
US20110159069A1 (en) * 2008-12-26 2011-06-30 Shaw Wendy J Medical Implants and Methods of Making Medical Implants
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US20100241220A1 (en) * 2009-03-23 2010-09-23 Mcclain James B Peripheral Stents Having Layers
US20100239635A1 (en) * 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
US20100256746A1 (en) * 2009-03-23 2010-10-07 Micell Technologies, Inc. Biodegradable polymers
US20100256748A1 (en) * 2009-04-01 2010-10-07 Micell Technologies, Inc. Coated stents
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
US10653820B2 (en) 2009-04-01 2020-05-19 Micell Technologies, Inc. Coated stents
US11369498B2 (en) * 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US20110190864A1 (en) * 2010-02-02 2011-08-04 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US20110238161A1 (en) * 2010-03-26 2011-09-29 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US9687864B2 (en) 2010-03-26 2017-06-27 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
WO2011130448A1 (en) * 2010-04-16 2011-10-20 Micell Technologies, Inc. Stents having controlled elution
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US11904118B2 (en) 2010-07-16 2024-02-20 Micell Medtech Inc. Drug delivery medical device
US10293050B2 (en) 2010-09-09 2019-05-21 Micell Technologies, Inc. Macrolide dosage forms
US9636309B2 (en) 2010-09-09 2017-05-02 Micell Technologies, Inc. Macrolide dosage forms
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10729819B2 (en) 2011-07-15 2020-08-04 Micell Technologies, Inc. Drug delivery medical device
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants

Also Published As

Publication number Publication date
WO2007011708A3 (en) 2007-06-28
US20160015537A1 (en) 2016-01-21
WO2007011708A2 (en) 2007-01-25
WO2007011708A8 (en) 2007-04-26
US10835396B2 (en) 2020-11-17

Similar Documents

Publication Publication Date Title
US10835396B2 (en) Stent with polymer coating containing amorphous rapamycin
CA2697239C (en) Method and system for coating a surface of a medical device with a therapeutic agent and drug eluting medical devices made thereby
US11911301B2 (en) Polymer coatings containing drug powder of controlled morphology
Steckel et al. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide
JP4243697B2 (en) Coating medical device using air suspension
Martin et al. Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology
JP3986086B2 (en) Particle precipitation method and coating method using near-critical and supercritical anti-solvents
US5833891A (en) Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US8669360B2 (en) Methods of converting amorphous drug substance into crystalline form
JPH0419910B2 (en)
US20040089230A1 (en) Mechanical and acoustical suspension coating of medical implants
JP2002508248A (en) Spin coating method and apparatus for liquid carbon dioxide system
US20110092900A1 (en) Method for Producing a Bioactive Surface on an Endoprosthesis or on the Balloon of a Balloon Catheter
Foster et al. Application of dense gas techniques for the production of fine particles
CN108261569B (en) Preparation method of medicine balloon
Zohrabi et al. Diphenylalanine peptide nanotubes self‐assembled on functionalized metal surfaces for potential application in drug‐eluting stent
MXPA04010018A (en) Aerosol containing a particulate active substance.
WO2000074657A1 (en) Methods for coating particles and particles produced thereby
CA2544376A1 (en) Method for preparing drug eluting medical devices and devices obtained therefrom
WO2009081048A2 (en) Desensitisation by coating crystals of explosive energy substances, coated crystals of such substances, and energy materials
US8357251B2 (en) Powder processing method
Mirza et al. Particle engineering in the perspective of thermodynamics: a case study with itraconazole
Morand et al. Aerosol‐assisted open‐air plasma deposition of acrylate‐based composite coatings: Molecule release control through precursor selection
KR20150083841A (en) Multilayer biodegradable microparticles for sustained release of therapeutic agents
EP3827115A1 (en) Drug crystallization under microgravity conditions

Legal Events

Date Code Title Description
AS Assignment

Owner name: MICELL TECHNOLOGIES, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAYLOR, DOUG;DEYOUNG, JAMES;MCCLAIN, JIM;REEL/FRAME:021102/0582;SIGNING DATES FROM 20080611 TO 20080613

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION